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Cancer is a broad term to describe a large variety of diseases with multiple 
factors influencing the outcome, among them, obesity and hyperlipidemia are 
known to contribute significantly to oncogenesis and cancer progression. The 
phenomenon is widely recognized, however the mechanisms underlying the 
effects are not understood. A number of processes may be involved, such as 
modulation of insulin signaling, alterations in steroid hormones, activation of 
inflammatory processes, or the accumulation of carcinogenic metabolites. 
However, there is emerging evidence that many of the known pathological 
effects of lipids are mediated directly by cell surface receptors that possess high 
affinity and specificity such signaling lipids. Recently it has been established 
that certain free fatty acids (FFAs) act as specific agonists for a family of four 
G protein-coupled receptors-FFAR1, FFAR2, FFAR3, and GPR120. These 
receptors participate in the regulation of glucose and lipid metabolism, but new 
data are emerging that implicate them in the progression of cancer. This study 
focuses on investigating FFARs in mediating signaling pathways that 
contributes to the progression of cancer, thus corresponding to accumulating 
questions regarding the mechanistic relationship between obesity and cancer.  
In this study, we demonstrate that activation of FFAR2 to leads to enhanced E 
cadherin and lowered vimentin levels, which is correlated with reduced cell 
invasion and phenotypic morphological changes. In addition, FFAR2 is shown 
to inhibit YAP activation by improved activity of LATS1 and LATS2. 
However, the receptor activation did not change the ERK/p38MAPK levels. On 
the other hand, FFAR3 is also determined to regulate vimentin levels which 
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corresponds with the morphological changes and invasive nature of the cells. 
Moreover, FFAR3 over-expression reduces the activation of ERK/p38MAPK 
levels. These findings suggest anti-proliferative and anti-metastatic roles of 
FFAR2 and FFAR3. Both FFAR2 and FFAR3 are shown to increase the 
sensitivity of the cells towards chemotherapeutic drugs. In addition, Curtis 
breast dataset indicates a reduced expression of both FFAR2 and FFAR3 in a 
panel of breast carcinoma tissues. Together, it suggests that FFAR2 and FFAR3 
activation in breast cancer inhibits the cancer promoting pathways.     
In contrast to FFAR2 and FFAR3, FFAR1 is studied for its role in tumor 
promoting properties. FFAR1 is shown to significantly activate ERK levels 
upon oleate stimulation in over-expression model. The activation was further 
improved upon GW9508, agonist application and reversed upon antagonist 
(GW1100) administration. FFAR1 over-expression also induced mesenchymal 
marker levels, such as Focal adhesion kinase (FAK) and vimentin along with 
significant morphological alterations. These findings suggest the role of FFAR1 
in promoting proliferation and metastasis in breast cancer. 
Conclusively, FFAR2 and FFAR3 are demonstrated to regulate tumor 
suppression, whereas FFAR1 positively regulates tumor progression. Further 
studies on FFARs can assist targeting the receptors for a better therapeutic 


















Chapter 1- Introduction 
Project overview: Free fatty acids are an essential macronutrient and key 
component of energy storage. The role of fatty acids has been implicated in 
various physiological functions. Additionally, a plethora of studies have 
identified that fatty acid is capable of regulating gene expressions through 
various means, for example, by engaging with Peroxisome Proliferator 
Activated Receptors (PPAR), a nuclear receptor and sterol regulatory element 
binding proteins (SREBP), a transcription factor. In the past decade, a group of 
receptors called Free Fatty Acid Receptors (FFARs) belonging to seven 
transmembrane G- Protein Coupled Receptor superfamily, was determined to 
signal fatty acids intracellularly, proceeding further to regulate the multiple 
cellular responses. This family of receptor was deorphanised by three 
independent group of researchers in 2003. FFAR family comprises of three 
major members, FFAR1, FFAR2 and FFAR3. From compound evidence, it is 
recognized that FFAR1 signals the Long Chain Fatty Acids (LCFAs), including 
unsaturated fatty acids like oleate and saturated fatty acid like palmitate, 
whereby, FFAR2 and FFAR3 signals Short Chain Fatty Acids (SCFA) like 
butyrate and propionate. various studies are generated concerning the functions 
of these receptors. FFARs are determined to regulate diverse physiological 
functions such as insulin secretion, anti-inflammatory responses, apoptotic 
effects, incretin release, adipogenesis and central nervous system regulated pain 
modulation. In the recent past, studies involving FFARs in association with 
cancer-related processes have been emerging. Reports have shown contrasting 
evidence for the roles of FFARs in cancer processes.   
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Studies show that FFAR2 and FFAR3 exert anti-tumor activities. Butyrate, a 
potent ligand for FFAR2 and FFAR3, particularly plays a role in inducing 
growth inhibition through apoptosis and HDAC inhibition in human colon and 
gastric cancer cell lines. However, the involvement of FFAR2 and FFAR3 in 
mediating these effects is not understood. In colorectal carcinoma, it was found 
that FFAR2 expression was lost, in addition, FFAR2-mediated inhibition of cell 
proliferation was observed. On the contrary, a study has recorded oncogenic 
role of FFAR2. Relatively, fewer studies are available on FFAR3 mediated 
cancer responses. A clear understanding of the function of SCFA receptors in 
cancer is not available. Thereby, this part of the project focuses on identifying 
the plausible role of the receptors in modulating breast cancer. Here, we 
determine that FFAR2 and FFAR3 trigger the effectors of anti-tumor pathways 
in breast cancer cells.  
On the contrary to FFAR2 and FFAR3, increasing evidence indicate the role of 
FFAR1 in mediating cancer promoting functions. FFAR1 is shown to increase 
cellular proliferation of breast and ovarian cancer cells. With regard to the most 
recent studies, contrastingly, the downregulation of FFAR1 promotes 
proliferation and migration in melanoma, fibrosarcoma and pancreatic cancer 
cells.  Thereby, this part of the project centers the role of FFAR1 in regulating 
tumor-promoting pathways. We identify that FFAR1 induces the mediators of 
tumor-promoting pathways, indicating FFAR1 supports tumor progression. In 
addition, we investigated the FFAR1 –mediated autophagy. Autophagy is 
accounted for both tumor- promoting and tumor- suppressing roles. In 
autophagy deficient condition, an aggregation of oxidative stress and chronic 
tissue damage induces tumor initiation, whereas in deregulated proliferative 
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cancer state, an increased autophagy process enhances the stress tolerance 
leading to promotion of tumor. Fatty acids, particularly, palmitate and oleate 
facilitated autophagy has exhibited opposing outcomes. We intended to 
understand the function of FFAR1 in modulating autophagy breast cancer cells.  
Evaluation of the mechanism underlying the fatty acid/FFAR mediated 
signaling pathway remains unclear. This study has successfully characterized a 
few, yet, crucial FFAR- mediated signaling pathways in modulating breast 
cancer. Further exploration in this front will enable us to understand its potency 
as a prospective therapeutic target in breast cancer management.  
1.1 G-Protein Coupled Receptors (GPCRs) 
	
GPCR is a large class of membrane protein, which senses a range of molecule 
outside of the cells and the signal is further amplified intracellularly, promoting 
various cellular processes. GPCRs are involved in regulating multiple cellular 
responses and physiological functions. They selectively binds to a variety of 
ligands such as light-sensitive compounds, pheromones, hormones, and 
neurotransmitters, therefore it is not surprising that GPCRs are correlated with 
various disorders and are targets for more than a quarter of clinically used drugs 
(Rosenbaum, Rasmussen et al. 2009). GPCRs are structured to have seven 
transmembrane spanning-helical structure, which has 3 compartments- the 
intracellular, transmembrane and extracellular loops. In most of the cases, extra 
cellular loop is where the ligand binds to and the intracellular loop is responsible 
for binding to G- proteins (Figure 1). The best explained mechanism through 
which GPCR mediates the signals is by involving heterotrimeric G proteins, 
though GPCRs are capable of signaling independent of G proteins. This large 
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family of transmembrane protein can be classified on the basis of various 
methods. According to International Union of Basic and Clinical 
Pharmacology, GPCRs are classified on the basis of ligands. The other 
method is based on sequence similarity which classifies GPCRs into 5 
families, Family A- Rhodopsin, Family B- Secritin, Family C- Glutamate, 
Adhesion and Family F- frizzled/taste. Among these members, family A- 
Rhodopsin is the largest and diverse family (Fredriksson, Lagerström et al. 
2003). Out of approximately 800 GPCRs in human genome, about 350 receptors 
are involved in regulating the development and physiological functions of 
human, thus making these receptors potential targets for drug discovery (Herr 
2012). Currently, about 30-50% of drugs and 20% FDA approved drugs act 
through GPCRs (Garland 2013), which makes the study of GPCRs more 
significant and essential.          
  
Figure 1: Structure of G Protein Coupled Receptors  
Figure represents the typical seven transmembrane receptors with G protein 
(subunits α, β, and γ) and ligand binding loops. The membrane divides the 
receptor into the extracellular part, transmembrane helices, and the intracellular 
part (Neumann, Khawaja et al. 2014). 
	 5	
1.1.1 GPCR mediated activation of G protein 
 
GPCRs are activated upon the binding of specific ligand. The ligand binds to 
the extracellular loop of the receptor, which brings about conformational 
structural changes enabling the activation of heterotrimeric G proteins. The 
activated G proteins stimulates the secondary messengers and its respective 
downstream effectors, thus regulating cellular events. The heterotrimeric G 
protein comprises of 3 subunits such as a-, b-, and g-subunits. The cycle of 
GPCR activation involves disassociation of a- subunit from bg-subunit, which 
involves the guanine nucleotide exchange factor (Figure 2). GPCR activation is 
described in steps below 1) Upon ligand binding the GPCRs undergo structural 
changes which facilitates the activation of G proteins. 2) The activated GPCR 
forms a complex with G protein and ligand. The activated G protein exchanges 
GDP (Guanine diphosphate) for GTP (Guanine triphosphate). 3) the GTP bound 
a-subunit destabilizes and separates from the bg-subunits. 4) thus activated a-
subunit and disassociated bg-subunits carry out specific downstream molecular 
events regulated by the cellular second messengers such as, cAMP and calcium 
levels. 5) After activating the signaling responses, a-subunit in GTP bound 
active state, now undergoes hydrolysis to exchange GTP for GDP, resulting in 
cessation of a-subunit activity. 6) The inactive a-subunit re-associates with bg-
complex thus terminating the GPCR activation cycle. Generally, the GPCR 
activation cycle is rapid and lasts for a few milliseconds (Frank, Thumer et al. 
2005).            
The helical structure of a-subunit ascertains specific binding to G protein 
(Lambright, Noel et al. 1994). The a-subunit interacts with b-subunit at its N-
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terminal region, whereas the C terminal and extreme N terminus is involved in 
recognizing GPCRs. bg-complex comprises of two polypeptides but 
functionally they are monomers which do not disassociate in the cells. bg-
complex interacts with a-subunits at the hydrophobic pocket in GDP coupled 
a-subunits, after the GTP exchange occurs in a-subunits the complex 
disassociates due to decreased affinity (Schwindinger, Betz et al. 2003).  
G proteins are classified on the basis of various isoforms of the components of 
heterotrimeric proteins. There are 16 types of  a-subunits, 5 b-subunits and 14 
g-subunits in humans and mouse (Simon, Strathmann et al. 1991)  (Fishburn, 
Herzmark et al. 1999).  
 
Figure 2: Activation and Deactivation cycle of GPCRs 
Schematic representation of mechanism of GPCR activity: GPCR activation and 
deactivation cycle involving G proteins, which shows the exchange of GDP for 
GTP in a-subunits upon activation and vice versa upon the termination of 
GPCR activation cycle. (Rasmussen, DeVree et al. 2011).  
 
1.1.2 Subfamilies of Ga subunit and its signaling effectors    
 
There are four major classes of Ga proteins that activate a variety of distinct 
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downstream mediators (Table 1 & Figure 3). Gai/o is the largest among the 
members. The members of Gai/o are sensitive to pertussis toxin (PTX) except for 
Gaz. Activated Gai, Gao, and Gaz subunits inhibits the activity of adenylyl 
cyclase. Gai1, Gai2, Gai3 subunits regulates the calcium currents and physiological 
functions like insulin secretion in adipose tissue and inflammatory responses 
(Ivanina, Rishal et al. 2003) (Gordeladze, Hovik et al. 1997) (Fan, Zingarelli et 
al. 2005). Gao and Gaz are highly present in nervous system (Strittmatter, 
Valenzuela et al. 1990) and cells exhibiting exocytosis (Andric, Zivadinovic et 
al. 2005). Gat1 and Gat2 are retinal G proteins (Stryer 1991). Gag is expressed in 
taste determining tissues and regulates related signal transduction (McLaughlin, 
McKinnon et al. 1992) (Hoon, Adler et al. 1999). 
The Gas induce adenylyl cyclase, which is known to produce the secondary 
messenger, cAMP (Taussig and Gilman 1995). Upregulated cAMP levels 
activate protein kinase A (PKA) and its respective downstream effectors. Gas is 
engaged in various processes that include regulation of bone growth, insulin 
sensitivity, immune responses (Bastepe, Weinstein et al. 2004) (Lu, Lee et al. 
1999) (Yu, Castle et al. 2001). Pancreatic cells and olfactory neurons are shown 
to express Gaolf  (Regnauld, Leteurtre et al. 2002). 
The Gaq G protein subfamily is shown to increase the levels of phospholipase C 
which is involved in the conversion of PIP2 to IP3 and DAG. The increased IP3 
level further goes on to release the intracellular stores of calcium and Protein 
Kinase C (PKC) (Berridge 1993) (Exton 1996). Gaq subunits have been 
accounted for activation of a K+channel (Shi H 2004). Gaq and Ga11 are 
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ubiquitously expressed in human tissues while Ga14  is principally seen in spleen, 
lung, testes, kidney and Ga16 is restricted to hematopoietic lineages (Wilkie, 
Scherle et al. 1991).  
The Ga12 subfamily has two members, Ga12 and Ga13 (Hall 1998) (Gohla, 
Schultz et al. 2000). Ga12 and Ga13 is shown to regulate RhoA by means of 
guanine nucleotide exchange factor thereby managing the effector pathways. 
Ga12 and Ga13 activated pathway is involved in various cellular events such as 
cell cycle regulation and cytoskeletal arrangements (Riobo and Manning 2005) 
(Hart, Jiang et al. 1998). Receptors that couple to Ga12/13 are also shown to 
couple Gaq in some cases, thus making the occurrence more complex to 
determine the cellular actions specific to Ga12/13.
  
Figure 3: G Protein-mediated activation of downstream effectors 
Figure illustrates the G protein dependent activation of second messengers and 
downstream signaling pathway (Cheng, Garvin et al. 2010). 
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Table 1: Members of the major Ga protein family and their downstream 
effectors. Adopted from (Thomsen, Grottick et al. 2008). 






Gas 	 Activation of adenylyl 
cyclase and src 
Gaolf adenylyl cyclase 
activation  
Gai/o Gai1, Gai2, Ga13, 
Ga0A, GaoB,  
Inhibition of adenylyl 
cyclase   
Gaz Inhibition of adenylyl cyclase; GRINI, Eya2 




Gaq Gaq Stimulation of PLCb, PLD; activation of 
RhoGEF  
Ga11 activation of PLCb; 
stimulation of Brunton’s 
tyrosine kinase; 
activation of RhoGEF  
Ga14, Ga15/16 Stimulation of PLCb  
Ga12/13 Ga12 , Ga13 stimulation of 
p115RhoGEF, PDZ-
RhoGEF, lbc-RhoGEF, 
Ga13 LARG, interaction 
with glutamate 
transporter associated 
protein GTRAP4, cell 
adhesion molecules.  
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1.1.3 Desensitization of G Protein-Coupled Receptors 
 
GPCR function is generally terminated by a widely-accepted mechanism: 
desensitization of GPCRs, involving three steps:  
(1) The ligand stimulated conformational change in GPCRs results in the 
phosphorylation of intracellular loop 2, intracellular loop 3 and C terminal. Thus 
phosphorylated GPCR is targeted to the clatherin coated pit facilitated by the 
recruitment of b-arrestin to the plasma membrane;  
(2) Following b-arrestin recruitment the receptor is detached by a dynamin-
mediated endocytosis method and thereby dissociates from the ligand within the 
endosomes;  
(3) Due to internalization of GPCR, there is a significant reduction or loss of the 
receptor. The internalized GPCR is shuttled back to the membrane surface 
following the disassociation with b-arrestin or it is degenerated by lysosomal 
activities. (Ferguson 2001) (Milasta, Evans et al. 2005).  
1.1.4 Constitutive activation of GPCRs 
 
GPCRs have a balance between their active and inactive state. The activation 
and deactivation cycle of GPCRs is critical to maintain normal physiology 
(Lefkowitz, Cotecchia et al. 1993). As discussed in the earlier sections, in 
normal physiology, the ligand bound GPCR results in the activation of G-
protein and its corresponding downstream effectors. Nevertheless, 
concentration of active state of the GPCRs is achievable in the lack of ligand-
GPCR contact. Pathological mutations leads to an increased activation of the 
receptor referred to as constitutive active mutants (CAM) on the other hand, a 
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decreased basal activation of the receptor referred to as constitutive inactive 
mutants (CIM) (Cotecchia, Fanelli et al. 2003) (Kleinau, Jaeschke et al. 2008). 
Reports have indicated that repetitive application of natural ligands to the GPCR 
leads to constitutive active conformations of the receptor. Based on the 
observations it is understood that GPCRs can be induced by modifying the 
protein sequences necessary for managing the tertiary protein structure 
(Alewijnse, Timmerman et al. 2000) (Parnot, Bardin et al. 2000) (Nakabayashi, 
Kudo et al. 2000). The accurate mechanism for constitutive activation is yet to 
be established. Diffraction studies have shown that switching from inactive to 
active position of the GPCRs might involve modification of transmembrane-III 
(TM-III) and TM-VI with concomitant rotation (Palczewski 2000). The amino 
acid constitution of the hydrophobic ‘latch’ region linking TM-III to TM-VI is 
determined to be the cause for constitutive activation in class I GPCRs (Lu, 
Saldanha et al. 2002) 
About 40–50% of all contemporary and almost 25% of the prime 200 best 
retailing drugs target GPCRs as per the current market status. GPCR-targeted 
drug development is successful for multiple disease ailments such as, 
gastrointestinal disease, CNS and immune- related complications, 
cardiovascular afflictions and metabolic disorders like diabetes and cancer. 
Approximately 210 GPCRs have been studied for their endogenous ligands 
which serves to be an essential target for drug discovery (Drews 2000) (Brink, 
Harvey et al. 2004).   
1.2 The discovery of Free Fatty Acid Receptors 
 
Free fatty acids are believed to exert their physiological functions by binding to 
fatty acid binding proteins (FABP) intracellularly or by binding to nuclear 
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receptor peroxisome proliferator-activated receptors (PPARs): PPARs are 
intracellular lipid sensors that promote oxidation of fatty acids and synthesis of 
ketone bodies (Ferre 2004). However, several physiological functions of FFA 
were demonstrated to be independent of PPARs, and were found to involve G 
protein signaling (Louet, Chatelain et al. 2001) (Sauer, Dauchy et al. 2000). This 
is consistent with the GPCR- mediated signaling of other bioactive lipids such 
as the sphingolipids (Hannun and Obeid 2008). These expectations were borne 
out with the discovery of the free fatty acid receptors (FFARs) over the last 
decade, thus introducing a new paradigm of free fatty acids as extracellular 
signaling molecules. 
In the process of cloning a gene encoding for receptor galanin, a new cluster of 
four intronless genes has been identified in the human genome (Sawzdargo, 
George et al. 1997). This cluster was located on the chromosome 19q13 and 
contained genes that were predicted to be rhodopsin-like receptors, namely 
GPR40 (FFAR1), GPR41 (FFAR3), GPR42 and GPR43 (FFAR2) (Sawzdargo, 
George et al. 1997). Although these receptors are the members of the same 
family, they possess limited similarity amongst them: FFAR2 and FFAR3 
shares 43% similarity and FFAR1 shares 33% and 34% similarity with FFAR2 
and FFAR3, respectively (Stoddart, Smith et al. 2008).  Three independent 
groups deorphanised GPR40, GPR41 and GPR43 in 2003, thereby identifying 
that GPR41 (FFAR3) and GPR43 (FFAR2) to be activated by short chain fatty 
acid activated (SCFA) and GPR40 (FFAR1) to be activated by medium and long 
chain fatty acid (MCFA/LCFA) (Le Poul, Loison et al. 2003) (Nilsson, 
Kotarsky et al. 2003) (Briscoe, Tadayyon et al. 2003) (Brown, Goldsworthy et 
al. 2003). These receptors were consequently renamed, GPR40 as free fatty acid 
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receptor 1 (FFAR1), GPR43 as free fatty acid receptor 2 (FFAR2) and GPR41 
as free fatty acid receptor 3 (FFAR3). 
Intriguingly, an additional gene called GPR42 was detected in humans and 
chimpanzees (Brown, Goldsworthy et al. 2003). In humans this gene is located 
in the FFAR family cluster, sharing 98% aminoacid homology with FFAR3, 
however this gene is considered to be a pseudo-gene as it did not display any 
activity in functional assays (Sawzdargo, George et al. 1997). Other FFARs 
activated by MCFAs and LCFAs yet, sharing only 10% identity with FFAR1 is 
GPR120, also known as FFAR4 (Costanzi, Neumann et al. 2008) and GPR84 
(Pu, Peng et al. 2011).  
There has been a constant augmentation of interest in FFAR family of receptors 
for their potential roles in various physiological activities extending from 
induction of insulin secretion, progress in adipose function, pancreatic cell 
viability and maintaining energy homeostasis (Dranse, Kelly et al. 2013) 
(Gotoh, Hong et al. 2007) (Butcher, Hudson et al. 2014). The role of FFARs in 
multiple diseases like cancer, cardiovascular diseases and rheumatoid arthritis 
is also reported (Talukdar, Olefsky et al. 2011) (Wu, Zhou et al. 2012). This 
family of receptors has shown an equally promising ability to serve as a 
therapeutic target for diverse pathological conditions such as metabolic disease.  
 
1.2.1 Free Fatty Acids  
 
Fatty acids are essential source of energy. Fatty acids are hydrocarbon chain 
with a carboxyl group (COOH) and a methyl group (CH3). Approximately 85g 
of fat is consumed by an adult on daily basis, of which most of it are 
triacylgelcerols. During the digestion process, free fatty acids and 
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monoacylglycerols are released which are reabsorbed in the small intestine. The 
re-esterified free fatty acid in intestinal mucosal cells is transported as a part of 
chylomicrons via lymphatic vessels into the circulatory system, they are further 
transported to the tissues in an albumin bound state. Furthermore, these fatty 
acids enter the cells with the facilitation of fatty acid binding proteins (FABP). 
The FFA upon entering the cells reaches mitochondria or peroxisomes for the 
ß-oxidation process to form ATP. Acyl-CoA or certain FFA can also regulate 
gene expression by binding to transcription factors thus bringing about 
alterations in cellular processes (Stulnig 2003). On the basis of the number of 
carbons in fatty acid chain, fatty acids are classified into 3 categories, Long-
Chain fatty acid (LCFA), ranging from 12 to 24 carbons (e.g. palmitic, stearic), 
Medium-chain fatty acids (MCFA) 8 to 10 carbons (e.g. lauric acid), Short-
chain fatty acid (SCFA) 2 to 6 carbons (e.g. propionate, butyrate, and acetate) 
(Leonard, Pereira et al. 2004). Free fatty acids are further categorized on the 
basis of the saturation of carbon atoms, such as, saturated FAs (SFAs) have 
single bonds saturated with hydrogen atoms, while unsaturated fatty acid are 
divided into two more types- mono- (MUFA) and poly- unsaturated FAs 
(PUFAs) having one or more double bonds, respectively. Plasma consists of 
35% saturated and 65% unsaturated fatty acids. The more double bonds a fatty 
acid has, the more unsaturated it is, giving it a less regular shape and decreased 
melting point (Hardman 2004) (Calviello, Serini et al. 2007)  
1.2.2 Short Chain Fatty Acids (SCFAs)  
 
Fatty acids that consists of less than six carbon atoms are short chain fatty acids, 
which includes acetate, propionate and butyrate that constitutes for about 95% 
of SCFAs production in total in human body (Bergman 1990). Approximately 
	 15	
300mM SCFA is produced by the process of fermentation in colon region 
whereby about 90% is absorbed through the luminal membrane. A ratio of 3:1:1 
exists with an average fecal concentration of about 40mM acteate, 15mM 
propionate, 14mM butyrate (Fernandes, Su et al. 2014). 5 to 10% of the total 
energy demand of the body depends on SCFAs (McNeil 1984) (Topping and 
Clifton 2001). Bacterial fermentation of carbohydrates, especially dietary fiber 
yields SCFA as a major by-product (Andoh, Tsujikawa et al. 2003). Dietary 
fibres are beneficial for the digestive system by reducing the cholesterol and 
blood levels (Brown, Rosner et al. 1999) (Brown, Rosner et al. 1999). In 
addition, the beneficial effects of dietary fibre intake is attributed to its 
metabolites i.e., SCFA (Canfora, Jocken et al. 2015). A large amount of butyrate 
is absorbed in the colon region and supplies energy to the colonocytes (Wong, 
de Souza et al. 2006). Whereas, propionate and acteate enters the circulatory 
system, where propionate is greatly absorbed by the liver in a vitamin B12-
dependent manner and controls the gluconeogenesis (De Vadder, Kovatcheva-
Datchary et al. 2014). Acetate is absorbed by liver as well as peripheral tissues 
(Cummings, Pomare et al. 1987). The concentrations of SCFA in peripheral 
circulation is as follows; butyrate ranging from 1 to 3 µM, propionate ranging 
from 4 to 5µM whereas acetate around 100 to 150µM (Siler, Neese et al. 1999). 
Short chain fatty acids are involved in a variety of physiological functions 
(Figure 4). Butyrate is potent in acting as a HDAC inhibitor (Theriot, 
Koenigsknecht et al. 2014) as well as modulate cell proliferation and 
differentiation (Daly and Shirazi-Beechey 2006) (Furusawa, Obata et al. 2013). 
SCFAs are also known to suppress colon inflammation  by regulating NFκB 
(Inan, Rasoulpour et al. 2000). SCFAs are demonstrated to take part in appetite 
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management by stimulation of secretion of leptin (Xiong, Miyamoto et al. 
2004), and directly involving stimulation of brain center in appetite control 
(Frost, Sleeth et al. 2014).  
             
	
Figure 4: Physiological functions of Short Chain Fatty Acid 
  
Schematic representation of physiological functions of short chain fatty acids 
in different tissues (Canfora, Jocken et al. 2015) 
 
 
1.2.3 FFAR2 and FFAR3- GPCRs for Short Chain Fatty Acid 
 
Within the FFAR subfamily, FFAR2 exhibits the highest degree of homology 
with FFAR3 yet, they only share about 43% of amino acid sequence similarity 
(Costanzi, Neumann et al. 2008). Within this domain, the amino acid motif 
difference between FFAR2 (Glu-Arg-Tyr) and FFAR3 (Glu-Arg-Phe) leads to 
a distinction in structure-activity relationship between FFAR2 and FFAR3 but 
they are still responsive to similar range of SCFAs (Milligan, Stoddart et al. 
2009).  
The SCFAs: acetate, propionate and butyrate, are the most potent agonists for 
FFAR2 and FFAR3, with EC50 around 0.5 mM. The millimolar SCFA 
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concentrations required to activate FFAR2 and 3 suggest a low potency, 
especially when compared to other known GPCR ligands (Bain, Scott et al. 
2013). This low potency may be due to the relatively high concentrations of 
SCFAs found in the gut (20 to 60 mM) (Brown, Goldsworthy et al. 2003), which 
may restrict the systemic activation of FFAR2 and 3.  
In the search for ligands for FFAR2 and FFAR3, compound library screenings 
were performed. Unexpectedly, all compounds formulated as acetate ions were 
found to be able to stimulate human FFAR2 and 3. Further experiments with 
sodium acetate or ammonium acetate showed that acetate was sufficient to 
activate FFAR2 (Brown, Goldsworthy et al. 2003). Other SCFAs such as 
propionate or butyrate were also found to be ligands not only for FFAR2, but 
also for FFAR3, while a range of saturated and unsaturated medium- and long 
chain free fatty acids failed to activate FFAR2 and FFAR3 (Xiong, Miyamoto 
et al. 2004) (figure 5). Noteworthy, all three SCFAs showed a similar potency 
on FFAR2, acetate was almost inactive on FFAR3 (Brown, Goldsworthy et al. 
2003). Although both FFAR2 and FFAR3 respond to SCFAs, differences in 
signal transduction and expression patterns would support the idea that the two 
receptors play distinct physiological roles. However, the physiological 
functions of FFAR2 and FFAR3 remain to be clearly defined.  
         
Figure 5: Chemical structure of endogenous ligands of FFAR2 and FFAR3 
(short chain fatty acid- Acetate, Propionate and butyrate) 
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1.2.4 Free Fatty Acid Receptor 2 
 
1.2.4.1 FFAR2- Tissue Distribution 
 
FFAR2 seems to be present in various tissues, which includes adipocytes, gut 
and immune cells. FFAR2 mRNA was detected at a high level in subcutaneous, 
perirenal, mesenteric, parametrial and epididymal adipose tissues in mice. In 
these tissues, expression increased significantly under a high-fat diet (1.3 to 3-
fold induction), the most drastic effect appearing in mesenteric adipose tissue. 
Interestingly, the level of FFAR2 mRNA increased in the murine 3T3-L1 cell 
line as they differentiate from preadipocytes to adipocyte (Hong, Nishimura et 
al. 2005). Besides, FFAR2 expression was detected by immunohistochemistry 
in human and rat colon, in particular in enteroendocrine cells that express GLP-
1 and PYY (Kaji, Karaki et al. 2011) (Karaki, Mitsui et al. 2006) (Karaki, Tazoe 
et al. 2008) (Tazoe, Otomo et al. 2008) (Tazoe, Otomo et al. 2009). In rat, 
presence of FFAR2 mRNA has been confirmed by real-time PCR in the colon 
and in the proximal parts of the gut at a lower level (Dass, John et al. 2007). 
 
1.2.4.2 FFAR2- Physiological Functions 
 
Previous reports have identified the involvement of FFAR2 in various 
physiological functions. FFAR2 regulates differentiation of preadipocytes 
suggesting its role in lipid metabolism (Hong, Nishimura et al. 2005). FFAR2 
knock out animals have shown an increased control of glucose levels in high fat 
fed mice and also reduces the liver triglyceride and the levels of plasma lipids 
(Bjursell, Admyre et al. 2011). In addition, FFAR2 knockout mice put on a 
normal diet developed obesity, while FFAR2 over-expression mice fed with 
high fat diet retained the mice lean (Kimura, Ozawa et al. 2013). Similarly, a 
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few studies show that high fat diet can improve the expression of FFAR2 in 
liver and skeletal tissues (Cornall, Mathai et al. 2011) (Dewulf, Cani et al. 2011). 
SCFAs are implicated in leptin production, a hormone known for suppressing 
appetite. Studies have suggested the role of FFAR2 in actuating leptin secretion 
(Zaibi, Stocker et al. 2010). FFAR2 manifested improvement in leptin 
production and reduced lipolysis is also reported in adipose tissues (Ge, Li et al. 
2008). The role of FFAR2 in affecting the GLP-1 levels in both in vitro and in 
vivo system is established (Tolhurst, Heffron et al. 2012), however the clear 
mechanism is not understood. FFAR2 agonist is drawing attention for its 
therapeutic potential for diabetes and obesity.    
Since FFAR2 is highly expressed in immune cells, it is not surprising that it may 
be associated with inflammation. SCFAs are widely known to regulate 
inflammatory mediator production (Cox, Jackson et al. 2009). It is established 
that FFAR2 is involved in recruiting immune cells (Bindels, Dewulf et al. 2013) 
(Sina, Gavrilova et al. 2009) and polymorphonuclear cells towards the site of 
bacterial infection (Le Poul, Loison et al. 2003). This is further proven by in 
vivo studies in which SCFA-induced FFAR2 activation led to stimulation of 
chemotaxis of neutrophils in mice (Vinolo, Ferguson et al. 2011). Moreover, 
FFAR2 deficient mice have shown a significant alteration in inflammatory 
response (Maslowski, Vieira et al. 2009). In addition, FFAR2 is involved in the 
chemotaxis modulator property of the receptor  further proven by another study 
that demonstrated a reduced neutrophil migration when FFAR2 inhibitor, 
GLPG0974 was introduced (Bindels, Dewulf et al. 2013) (Figure 6). All these 
evidence suggest the essential role of FFAR2 in regulation of normal 
physiological processes and it proves the capability to serve a better therapeutic 
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target which led to discovery of multiple synthetic modulators, to mention a 
few, orthosteric agonist (2-methylacrylic acid), allosteric agonists (Compound 
58, Compound 34), inverse agonists (Compound 4) have been discovered 
(Bindels, Dewulf et al. 2013). Meanwhile, GLPG0974, a potent and selective 
antagonist of FFAR2, which inhibits FFAR2 mediated activation and migration 
of neutrophils, has demonstrated favorable safety profile and good 
pharmacokinetic and pharmacodynamics properties in Phase I clinical trial to 
treat patients with mild to-moderate ulcerative colitis (Pizzonero, Dupont et al. 
2014) (Tang and Offermanns 2016).  
 
1.2.4.3 FFAR2- Signal transduction 
 
Several publications explore the G protein coupling and downstream signaling 
of FFAR2 in different cell types and assays. A study on FFAR2 shows a specific 
coupling of FFAR2 with Gα12, Gα13, Gα14, Gαi1 and Gαi3 G proteins using a panel 
of yeast strains expressing a range of different yeast/mammalian Gα chimeras 
(Brown, Goldsworthy et al. 2003). Later studies with CHO and HEK293 cells 
expressing human FFAR2 demonstrated that acetate and propionate were able 
to induce Ca2+ mobilization and to decrease cAMP levels, suggesting a double 
coupling of the receptor with Gαi and Gαq proteins (Lee, Schwandner et al. 2008) 
(Stoddart, Smith et al. 2008).  
The downstream target of FFAR2 signaling includes mitogen-activated protein 
kinase (MAPK) p38 which was specifically phosphorylated upon FFAR2 
activation via SCFAs in MCF-7 cells (Yonezawa, Kobayashi et al. 2007). 
Similar p38 MAPK phosphorylation upon FFAR2 activation was observed in 
FFAR2 transfected CHO-KI and HEK293 cells (Le Poul, Loison et al. 2003) 
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(Seljeset and Siehler 2012). Yonezawa et al. reported absence of ERK 
phosphorylation upon FFAR2 activation (Yonezawa, Kobayashi et al. 2007). 
However, ERK phosphorylation upon FFAR2 stimulation with SCFA was 
observed by a different group of researchers (Seljeset and Siehler 2012). It 
appears that FFAR2 activation of ERK largely depends on upstream MEK 
kinase. It has been also shown that FFAR2 ligand propionate was not able to 
activate the c-Jun N-terminal kinase (JNK) (Yonezawa, Kobayashi et al. 2007) 
but FFAR2 transfected HEK293 showed weak JNK phosphorylation upon 
SCFA treatment (Seljeset and Siehler 2012). In addition to that, FFAR2 
manifests activation of AKT, PTEN and liver kinase B1 via Gβγ protein 
(Kimura, Ozawa et al. 2013). Although the studies provide evidence for the role 
of FFAR2 in exerting its mediated effects, specific mechanism behind these 
effects observed need to be studied, that will enable targeting FFAR2 for a better 
therapeutic purpose.   
        
Figure 6: Physiological functions of FFAR2 
Role of FFAR2 in lipid metabolism, GI tract function, glucose metabolism and 




PYY	production Chemotaxis Lipolysis GLP-1	secretion Cytokine	production
Appetite Anti-inflammation Insulin	sensitivity Glucose	secretion Anti-inflammation
SCFA
	 22	
1.2.5 Free Fatty Acid Receptor 3 
 
Although FFAR2 and FFAR3 share some similarities regarding their aminoacid 
sequences and ligands, FFAR3 exhibits its own specificity for G proteins, 
expression pattern and physiological roles. 
 
1.2.5.1 Tissue distribution 
 
FFAR3 seems to have a more widespread expression pattern than FFAR2. 
Significant levels of FFAR3 expression were detected in gastrointestinal tract, 
particularly in the ileum and the colon region in mouse and in human (Dass, 
John et al. 2007) (Tazoe, Otomo et al. 2009) (Samuel, Shaito et al. 2008). More 
precisely, FFAR3 was colocalized with cholecystokinin (CCK)-secreting cells 
in mouse and with PYY-secreting enteroendocrine cells in human (Samuel, 
Shaito et al. 2008). Remarkably, FFAR2 and FFAR3 are not localized in the 
same colonic enteroendocrine cells in human (Tazoe, Otomo et al. 2009). 
Expression of FFAR3 has been also found in adipose tissue, but this finding 
remains controversial. A few studies have detected FFAR3 mRNA in human 
adipocytes at high levels (Brown, Goldsworthy et al. 2003) (Xiong, Miyamoto 
et al. 2004) on the other hand, few other studies detect low levels of FFAR3 
mRNA in adipocytes (Le Poul, Loison et al. 2003) (Zaibi, Stocker et al. 2010). 
In the murine preadipocytic 3T3-L1 cell line, FFAR3 expression increased upon 
differentiation, although remaining at relatively low levels (Brown, 
Goldsworthy et al. 2003). However, a study has stated undetectable FFAR3 
mRNA level in a variety of adipose tissues from mouse or in differentiated 3T3-
L1 cells (Hong, Nishimura et al. 2005). FFAR3 mRNA has been successfully 
detected in subcutaneous and perirenal adipose tissues from goat at a substantial 
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level (Mielenz, Seybold et al. 2008). In addition, FFAR3 is expressed in the 
murine insulinoma cell line Min6, in mouse islets and in human pancreas 
(Leonard, Pereira et al. 2004) (Zaibi, Stocker et al. 2010) (Kebede, Alquier et 
al. 2009). Intriguingly, the FFAR3 was found to be highly expressed in 
pancreatic cells from diabetic mice compared to wild-type mice (Leonard et al. 
2007). Taken together, these results suggest a physiological role for FFAR3 in 
the gut, adipose tissue, and pancreatic islets. 
 
1.2.5.2 Physiological Functions 
 
FFAR3 has been demonstrated to play roles in energy homeostasis, sympathetic 
activation and improving insulin resistance. It is expressed in intestinal L cells, 
which involved in production of peptide YY (PYY). Through regulation of PYY 
secretion, FFAR3 is able to affect blood pressure by regulation of renin release 
as well as regulating gut motility and intestinal transit rate (Tolhurst, Heffron et 
al. 2012). Further supporting this, other studies demonstrated that absence of 
FFAR3 expression is associated with reduced PYY secretion and thus, resulted 
in increased gut motility and eventually weight loss (Zaibi, Stocker et al. 2010). 
Thus, this suggests the role of FFAR3 in energy homeostasis. 
FFAR3 is found to regulate the sympathetic nervous system upon SCFA 
activation. Under fed state, SCFA produced from the fermentation of dietary 
fiber is able to activate FFAR3 which induces sympathetic activation. However, 
under starvation, β-hydroxybutyrate, a metabolite by-product, inhibits FFAR3 
and sympathetic nervous system, suppressing energy expenditure, thus 
attributing the role of FFAR3 in energy conservation during state of fasting 
(López Soto, Gambino et al. 2014). This evidence demonstrated physiological 
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functions of FFAR3, especially in the case of energy homeostasis and 
expenditure in the body.  
It was first reported that FFAR3 is highly expressed in adipose tissue and 
stimulates leptin secretion after short-chain fatty acid stimulation (Xiong, 
Miyamoto et al. 2004). Over expression of FFAR3 led to an increase in leptin 
production, which was abolished by knockdown of FFAR3. In contrast, recent 
studies claims that  FFAR3 is not detectable in adipocytes, while the effects of 
short-chain fatty acids on leptin secretion might be mediated through FFAR2 
instead of FFAR3 (Zaibi, Stocker et al. 2010). Further investigation is needed 
to resolve this discrepancy. Recent studies also showed that FFAR3 is involved 
in inflammatory and metabolic diseases. Stimulation with butyrate attenuated 
inflammation and lipolysis in macrophages and white adipocytes, attenuation 
was abolished by blocking FFAR3 (Ohira, Fujioka et al. 2013). Interestingly, 
FFAR3 knock-out mice showed attenuated inflammatory responses in intestinal 
epithelial cells following ethanol or 2, 4, 6-trinitrobenzene sulfonic-acid 
(TNBS) treatment (Kim, Kang et al. 2013). Therefore, further investigation is 
needed to illustrate the link between FFAR3 and inflammation.  
Studies on these two receptors had been focusing mainly on normal 
physiological roles such as regulation of lipid metabolism and energy 
homeostasis, as well as on pathological conditions, especially metabolic 
disorders such as diabetes mellitus. Recent studies have shifted their focus to 





1.2.5.3 FFAR3- Signal Transduction 
 
Several reports suggest the coupling of FFAR3 solely with the pertussis toxin 
(PTX)- sensitive Gαi G protein (Brown, Goldsworthy et al. 2003) (Le Poul, 
Loison et al. 2003) (Xiong, Miyamoto et al. 2004). For example, in CHO-K1 
cells transiently expressing mouse FFAR3, SCFAs were able to suppress 
forskolin-induced cAMP production and this effect was sensitive to PTX (Le 
Poul, Loison et al. 2003). In HEK293T cotransfected with hFFAR3 (human 
FFAR3) and the Gai protein, SCFAs were able to activate the receptor in 
GTPγ[35S] assays (Brown, Goldsworthy et al. 2003). In Xenopus 
melanophores, heterologously expressing hFFAR3, stimulation with SCFAs 
provoked pigment aggregation, which indicates a decrease in cytosolic cAMP 
concentration (Xiong, Miyamoto et al. 2004). In contrast to FFAR2, FFAR3 
was not able to induce Ca2+ mobilization, unless it is artificially coupled to the 
chimeric Ca2+-inducing Gαq protein (Stoddart, Smith et al. 2008). 
 
1.2.6 Long Chain Fatty Acids (LCFA) 
 
Generally, fatty acids are grouped into different classes depending on the 
saturation of the carbon atoms, such as, saturated fatty acid (SFA) and 
unsaturated fatty acid. The unsaturated long chain fatty acid is further 
categorized into polyunsaturated (PUFA), monounsaturated (MUFA), trans 
fatty acid and omega- fatty acid [omega-3 fatty acid (n-3), omega-6 (n-6) and 
omega-9 (n-9) fatty acid], these different types of LCFAs have various sources 
of supply (Table 2). In addition to endogenous synthesis of saturated fatty acid 
and n-9 fatty acid from carbohydrates, dietary intake is another source of supply. 
On the other hand, human body is incapable of synthesizing n-3 and n-6 fatty 
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due to lack of enzyme that facilitates desaturation, therefore dietary supply is 
the only vital source. The parental source of n-3 and n-6 fatty acid is a-linolenic 
acid and linoleic acid taken in the diet which metabolizes to obtain n-3 and n-6 
fatty acids (Ratnayake and Galli 2009) (figure 7). The n-9 MUFA oleic acid 
(OA, 18:1) is the most common MUFA in human diet and generally MUFA 
composes 12% of dietary intake. Olive oil is rich in OA, but OA is also 
synthesized in the human body (Serini, Fasano et al. 2011) (Calviello, Serini et 
al. 2007). Table 2 presents the list of different types of long chain fatty acids 
and source of supply.  
 
Figure 7: A flow chart represents the Metabolism of w-3 and w-6 fatty acids 
 















Palmitic & Stearic  
 
 
16:0 & 18:0 
 
De novo synthesis, milk, 
































Desaturation of palmitic 
acid, fish oil 
 
Desaturation of stearic acid, 
milk, eggs animal fats and 
most vegetable oils 
 
Cannot be synthesized in 
mammals. Present in milk, 
eggs animal fats and meat.  
 
Synthesized from linoleic 
acid, borage, and evening 
primrose oils 
 
















Cannot be synthesized in 
mammals. Present in leafy 
greens, soybean oil, canola 
and linseed oils  
Synthesized from α-
linolenic, present in marine 






1.2.7 FFAR1- a GPCR for Long Chain Fatty Acids  
 
FFAR1 is the most characterised and well-studied receptor among the members 
of the family. Various studies have conclusively confirmed the role of FFAR1 
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in acute stimulatory effects of LCFAs in glucose-stimulated insulin secretion 
(Itoh, Kawamata et al. 2003) (Shapiro, Shachar et al. 2005). For its profound 
action in energy homeostasis, FFAR1 is targeted for Type 2 diabetes (T2D) 
management (Briscoe, Peat et al. 2006) (Feng, Leng et al. 2012). Among the 
FFARs, FFAR1 possesses a broad range of synthetic ligands which includes 
agonists such as GW9508, AMG837, MEDICA16 and TAK875, while 
antagonists such as GW1100, Pfizer compund 15i and DC260126 for its 
significant function in regulating insulin secretion (Milligan, Alvarez-Curto et 
al. 2015) (Briscoe, Peat et al. 2006) (Du, Dransfield et al. 2014) (Feng, Leng et 
al. 2012) (Hara, Kashihara et al. 2014) (Holliday, Watson et al. 2011) (Fjaere, 
Aune et al. 2014) (Kebede, Ferdaoussi et al. 2012) (Talukdar, Olefsky et al. 
2011). 
The FFAR1 agonist TAK-875 also improved glycemic control in a 12-week 
trial in Type II diabetes (T2D) patients (Burant, Viswanathan et al. 2012) (Kaku, 
Araki et al. 2013). The development of a promising selective partial agonist of 
FFAR1, TAK-875, was removed from phase II clinical trial due to its liver 
toxicity although it is not known whether the effect was candidate- or 
mechanism specific (Ichimura, Hasegawa et al. 2014) (Srivastava, Yano et al. 
2014).  
Agonists of FFAR1 are thus enthusiastically explored as Type II diabetes drugs 
with minimal risk of iatrogenic hypoglycaemia. 
 
1.2.7.1 FFAR1- Tissue Distribution 
 
The highest expression and strongest effects of FFAR1 is observed in pancreatic 
β-cells, mediating the glucose-stimulated insulin secretion (GSIS) by free fatty 
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acids. The pathway signals through FFAR1 - Gαq/11 - PLC - diacylglycerol - 
protein kinase D 1 (PKD1). PKD1 facilitates remodeling of filamentous-actin 
for the purpose of intracellular shuttling of insulin granules to the surface of the 
membrane for exocytosis (Mancini and Poitout 2013). Correspondingly, acute 
and chronic administration of FFAR1 agonists improved glycemic control in 
diabetic rodents (Tan, Feng et al. 2008) (Lin, Zhang et al. 2011) (Luo, 
Swaminath et al. 2012) (Tsujihata, Ito et al. 2011).  
In addition, FFAR1 mRNA is present in several other tissues or cells, such as 
the brain, liver, heart, skeletal muscle, immune cells, monocytes, in 
enteroendocrine cells and in breast cancer cells (Stoddart, Smith et al. 2008) 
(Figure 8). In 2008, Yonezawa et al. identified the FFAR1 ortholog in cattle; 
the amino acid sequence of the bovine FFAR1 is 84% and 82%, identical to the 
human FFAR1 and mouse FFAR1, respectively. Furthermore, FFAR1 mRNA 
was detected in bovine mammary epithelial cells as well as in the bovine 
mammary gland at different phases of lactation. The same study provided 
evidence that linoleic and oleic acid are involved in cellular signaling in bovine 
mammary epithelial cells through activation of FFAR1 (Yonezawa, Haga et al. 
2008). Another working group showed the presence of an FFAR1 ortholog in 
bovine neutrophils, suggesting that the oleic acid-induced release of granules 
from neutrophils is mediated by FFAR1 (Manosalva, Mena et al. 2015). 
Additionally, it seems that FFAR1 might also be involved in cell adherence, 
chemotaxis, release of granules in bovine neutrophils induced by linoleic acid 
(Mena, Manosalva et al. 2013).  
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Figure 8: Distribution of FFARs in different parts of the body (Ichimura, 
Hasegawa et al. 2014). 
 
1.2.7.2 FFAR1- Physiological functions 
 
In normal β-cell function, FFAR1 seems to play an important role with its ability 
to augment glucose-stimulated insulin secretion (GSIS) in response to short-
term elevated FFA in the circulation. This relationship has been studied in 
FFAR1 knockout mice models, where FFAR1 knockout mice showed a reduced 
capacity to augment GSIS on exposure to fatty acids (Steneberg, Rubins et al. 
2005) (Latour, Alquier et al. 2007). Despite the augmentation of GSIS by short-
term elevation of circulating FFA, their long-term elevation has been shown to 
impair insulin secretion. Knockout mice models also indicate that FFAR1 plays 
a role in glucagon release from α-cells (Flodgren, Olde et al. 2007) (Lan, Hoos 
et al. 2008) and in secretion of glucagon-like peptide (GLP)-1, glucose-
dependent insulinotropic polypeptide and cholecystokinin from murine 
enteroendocrine cells (Edfalk, Steneberg et al. 2008) (Liou, Lu et al. 2011). In 
addition, there is evidence of an involvement of FFAR1 in cell proliferation, 
breast cancer progression (Yonezawa, Katoh et al. 2004) (Hardy, St-Onge et al. 
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2005). Decreased hepatic lipid accumulation accompanied with decreased 
expressions of lipogenesis-related proteins in mice fed a high fat diet (Ou, Wu 
et al. 2014). Additionally, it seems that FFAR1 might also involve in adhesion, 
chemotaxis, granule release and intracellular responses in bovine neutrophils 
induced by linoleic acid (Mena, Manosalva et al. 2013) (Table 3) 


















1.2.7.3 FFAR1- Signalling pathway 
 
The introductory studies on FFAR1 implied that FFAR1 associates with Gaq/11  
G protein (Itoh, Kawamata et al. 2003) (Kotarsky, Nilsson et al. 2003) (Tan, 
Feng et al. 2008) (Schnell, Schaefer et al. 2007). Gaq/11 coupled GPCRs activate 
the phospholipase C (PLC), which further goes on to induce the hydrolysis of 
the second messengers, DAG and IP3. DAG and IP3 furthers the facilitation of 
PKC, which promotes the Ca2+ mobilization from endoplasmic reticulum stores 
(Latour, Alquier et al. 2007). Shapiro et al demonstrated that activation of 
FFAR1 is involved in glucose stimulated insulin secretion (GSIS), they studied 
Tissue distribution Functions 
Pancreatic b-cells Glucose-stimulated insulin 
secretion 
Enteroendocrine cells Incretin secretion 
Pancreatic a-cells Glucagon secretion 
Central nervous system Unknown function 
Taste buds Taste preference for fatty 
acids 
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by inhibiting Gaq/11 and identified that FFA potentiation of GSIS was blocked 
(Shapiro, Shachar et al. 2005) (Figure 9) and in addition, IP3 generation 
mediated by FFA was dependent on FFAR1 (Alquier, Peyot et al. 2009). A 
different report has shown that the mechanism behind the FFAR1- GSIS in β-
cells system involves cAMP-dependent PKC activation and decrease in voltage 
gated potassium channels thus leading to insulin release (Feng, Luo et al. 2006).   
Multiple groups have studied that FFA mediated augmentation of GSIS is 
dependent on Gaq/11/PδC-dependent signaling mechanisms. FFAR1 activation 
upon oleate mediated DAG subsequently resulting in PKD stimulation 
(Ferdaoussi, Bergeron et al. 2012). However, FFAR1 coupling is supported by 
a few studies. Data from a study shows that FFAR1 could couple to Gai/o (Itoh, 
Kawamata et al. 2003), similarly, FFAR1 weakly couples to Gai/o in MCF-7 
cells, in which PTX abrogated the LCFA-mediated elevation of [Ca
2+
] 
(Yonezawa, Katoh et al. 2004). A group has reported that FFAR1 agonists 
(oleate and linoleate) decreased cAMP production (Yonezawa, Haga et al. 
2008). Fujitha et al reported that GW9508 repressed CCL17 and CCL5 
expression in a PTX dependent fashion in keratinocytes (Fujita, Matsuoka et al. 
2011). To our knowledge, the only report that provided evidence for coupling 
between FFAR1 and Gas is by Feng et al (Feng, Luo et al. 2006). Linoleic acid 
significantly enhanced cAMP accumulation when combined with IBMX 
(phosphodiesterase inhibitor) or forskolin (adeno cyclase stimulator). An 
interesting finding states that GPCRs can associate to multiple G proteins 
(Mancini and Poitout 2013). GPCRs are capable of signaling independent of G 
proteins (potential cross talks) and in arrestin-dependent manner to initiate a 
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variety of cellular events. Whether this can be applied or not to the FFAR1 
receptors requires further investigation.  
 
                          
Figure 9: Mechanism of FFAR1-mediated GSIS in pancreatic cell. 
 
Mechanism of FFAR1 mediated insulin secretion involving PLC pathway and 




Cancer represents a significant public health issue in majority part of the world 
accounting for nearly 14 million new cases and 8.2 million cancer associated 
deaths. In the next 2 decades, the count is anticipated to ascend by around 70%. 
Among women 5 most prevalent cancer types diagnosed is breast, colorectum, 
lung, cervix, and stomach cancer (Neumann, Khawaja et al. 2014, Stewart and 
Wild 2014). Besides heart diseases, cancer is the predominant cause of death 
among men and women aged older than 40 years in western countries (Jemal, 
	 34	
Siegel et al. 2010). 
Decades of intense study on biology of cancer led to the conjecture that variety 
of mutations has led to an enhanced activation of oncogenes and inhibit the 
activity of tumor suppressors (Bishop, Weinberg et al. 1996). Generally, 
transformation of normal cells into malignant derivatives is a multistep process 
requiring alterations of the genome at multiple sites (Kinzler and Vogelstein 
1996). 
1.3.1 Hallmarks of Cancer 
 
Hanahan and R.A Weinberg in their publication in 2000 and in an update in 
2011, specified a small number of underlying principles responsible for the 
transformation (Hanahan and Weinberg 2000, Hanahan and Weinberg 2011) 
(figure 10): autonomous supply of growth factor, unresponsive to growth 
restraining signals, circumvention of programmed cell death (apoptosis), 
unbound potential to proliferate, sustained angiogenesis and tissue invasion and 
metastasis  
These six hallmarks of cancer were proposed to be shared in perhaps all types 
of cancer leading progressively to a neoplastic state. Furthermore, D. Hanahan 
and R. A. Weinberg noted that tumors are not just an isolated mass of actively 
dividing cells, but instead a congregate of tissues with multiple distinct cell 
types where even normal cells, such as fibroblasts and endothelial cells, are 
active participants of tumorigenesis and that this “tumor microenvironment” 
plays a crucial role in understanding the biology of tumors. 
Self-sufficiency in growth signals: over-expression of growth factor receptors 
(Alimandi, Wang et al. 1997) and oncogenes like Myc (Luscher 2001) and 
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altering proliferation signals for eg; Ras-Raf-MAPK cascade (Medema and Bos 
1993).   
Circumvention of programmed cell death: The ratio of cell growth to cell death 
attributes to the population size. Uncontrolled cell growth is impeded by a 
natural process called apoptosis, which is categorized under well-established 
process called programmed cell death. Procured resistance against apoptosis is 
another feature of cancer, like, increasing expression of anti-apoptotic 
regulators (Junttila and Evan 2009), elevated levels of autophagy due to stress 
stimuli (White and DiPaola 2009) and necrosis mediated proinflammtory 
signals (Grivennikov, Greten et al. 2010),  
Limitless replicative potential: In contrast to normal cells, cancer cells exhibit 
boundless replicative potential in order to develop a macroscopic tumor. During 
every cell cycle, due to the inability of DNA polymerases to completely 
replicate 3’ ends, a minor part of telomeres is lost, leading to complications 
(Zvereva, Shcherbakova et al. 2010).  
Sustained Angiogenesis: oncogene-mediated upregulation of pro-angiogenic 
factors leading to release and stimulation of matrix- degrading proteases (e.g. 
MMP-9) in the extracellular matrix results in sustained tumor angiogenesis  
(Kessenbrock, Plaks et al. 2010).  
Metastasis: metastasis is a multilevel process. Local invasion requires the down-
regulation of adhesion molecules such as E cadherin, which mediates cell-cell 
adhesion. The key coordinator of this process are a set of pleiotropic 
transcription factors, including Snail, Slug, Twist and Zeb 1/2, which govern 
one another as well as concurring sets of target genes (Micalizzi, Farabaugh et 
al. 2010) (Yang and Weinberg 2008). Following invasion, intravasation into 
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blood and lymphatic vessels, passage through lymphatic and hematogenous 
systems, extravasation, formation of micrometastases and ultimately, growth of 
a macroscopic tumor (Fidler 2003). 
Additional hallmarks of cancer as per Hanahan and Weinberg’s description are 
Genomic instability, generating random gene mutations and chromosomal 
rearrangements leading to enhanced proliferation and metastasis (Berdasco and 
Esteller 2010). The other enabling factor is inflammation by immune cells, 
release of different chemicals such as actively mutagenic reactive oxygen 
species, tumor associated inflammatory response can enhance tumorigenesis 




Figure 10: The Hallmarks of Cancer, enabling characteristics and emerging 
hallmarks. 




1.3.2 Breast cancer 
 
Breast cancer originates from breast tissue, more regularly from the inner lining 
of ducts or the lobules, in some cases, the tissues in between. The two sub types 
depending on the place of origin- from ducts called ductal carcinoma and other 
from the lobules called lobular carcinomas. Among humans, breast cancer is 
observed to be the majority of cases in women, however men can also be 
affected. Breast cancer is one of the critical diseases among women in the 
western countries resulting to be the most common and deadliest type of cancer 
in women on a global scale. Universally, breast cancer is the dominant type of 
cancer in women, close to 1.7 million new cases is diagnosed in 2012, depicting 
12% of new cancer types and 25% of total cancers in women (2015). A typical 
description generally considered for classifying breast cancer, involves each of 
these aspects: the histopathological type, the grade of the tumor, the stage of the 
tumor, and the expression of proteins and genes. The classification of breast 
cancer types on the basis of receptor expression, as follows	
Hormone receptor (estrogen/ER or progesterone/PR receptor) positive: Of all, 
75% and 65% of breast cancers develop in response to hormone estrogen (ER 
positive) and hormone progesterone (PR positive) respectively.  
HER2 positive: Constitutes about 20%- 25% of breast cancers, where the cells 
produce protein known as HER2/neu in excess, making it more aggressive and 
fast-growing. (Park, Koo et al. 2012). 
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Triple negative: Ranging between 10% and 17% of total types of breast cancer 
They are called as” triple negative” due to lack of estrogen, progesterone and 
HER2 protein. In addition, associated with BRCA1 gene mutation (Park, Koo 
et al. 2012). 
The breast cancer risk is found to associate with the life style, high fat diet, 
exposure to radiations and other causes. Likewise, the relationship between 
dietary fat intake and breast cancer has generated a substantial interest for 
decades. (Armstrong and Doll 1975) (Buell 1973) (Dunn 1977).  
  
1.4 Association between Fatty acids, FFARs and Cancer 
 
1.4.1 Short chain fatty acid and its association to cancer- A review on the 
role FFAR2 and FFAR3 in cancer  
 
Bile acids and dietary acids absorbed in form of dietary factor is shown to exert 
tumor-promoting actions, whereas, dietary fibers ingested is reported to 
function towards anti-tumorous activities (Weisburger 1991). Consumed 
dietary fiber, ferments to obtain short chain fatty acid as a main by-product. 
Studies about SCFAs, particularly butyrate is shown to exercise cellular growth 
inhibition and differentiation of colon cancer cells (Augeron and Laboisse 1984) 
(Whitehead, Young et al. 1986) by reducing PKC levels in 2 colon cancer cells 
Caco-2 and LIM1215 (Shao, Gao et al. 2004) (Duan, Heckman et al. 2005). In 
addition, report shows that in vivo butyrate levels reduce with the occurrence of 
colon cancer (Otaka, Singhal et al. 1989) (McIntyre, Gibson et al. 1993). Many 
studies on SCFA has focused on butyrate than other SCFAs. Butyrate is 
moreover shown to activate Cyclin D3 and p21 which results in arresting cell 
cycle at G1 stage (Boren, Lee et al. 2003). In addition to inhibiting cell growth, 
butyrate is demonstrated to reduce proliferation and stimulate caspase 3 leading 
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to apoptosis in Caco-2 cells and gastric cancer cells TMK-1, SIIA and SGC-
7901 (Rickard KL 2000) (Yan and Xu 2003) (Tsai and Yang 2013) (Litvak, 
Hwang et al. 2000). Comparatively, fewer studies have explored the roles of 
propionate in cancer. However, propionate is shown to decrease cellular 
proliferation in liver cancer cells, Inulin- Type fructan (ITF) is known to 
produce propionate upon bacterial fermentation. In In vivo model, Inulin- Type 
fructan (ITF) treatment has displayed reduced cellular infiltration and growth 
(Bindels, Porporato et al. 2012).   
Population-based epidemiological studies (Hennekens 1987), Correlation 
studies (Kim 2000), meta-analyses case control studies (Friedenreich 1994, 
Howe 1992, Trock 1990), a large cohort study (Thun 1992) and a study 
published in 1999 analyzed data from seven countries, following the subjects 
over 25 years (Jansen 1999), all the above-mentioned studies have found an 
inverse relationship between dietary fibre intake and colorectal cancer 
mortality. On a contrary, a few studies have shown no relationship (Fuchs 1999) 
or weak but statistically insignificant inverse relationship between dietary fibre 
intake and colorectal cancer or colorectal adenoma (Giovannucci 1992) (Platz 
1997).  
1.4.1.1 Possible role of FFAR2 and FFAR3 in cancer: the missing link 
 
The evidence for possible roles of FFAR2 in cancer has been accumulating over 
the past few years. In the recent years Hatanaka et al. (2010) showed that FFAR2 
coding gene may be an oncogene. The potential of FFAR2 to be oncogenic was 
confirmed by both in vitro and in vivo methods. The researchers confirmed 
FFAR2 oncogenic potential by the in situ hybridization using antisense FFAR2 
mRNA probe and by immunohistochemistry using anti-FFAR2 antibody 
	 40	
(Hatanaka, Tsukui et al. 2010).  They also showed the expression of FFAR2 is 
significantly higher in gastric and colorectal cancer specimens and FFAR2 
overexpression transformed NIH3T3 mouse fibroblast cells, which are 
tumorigenic in nude mice (Hatanaka, Tsukui et al. 2010). 	
Surprisingly, on the contrary FFAR2 was shown to have tumour suppressor 
function as well. Normal human colon cells, in general have high expression of 
FFAR2, but in most of the colorectal adenocarcinoma FFAR2 expression is lost 
or greatly reduced. FFAR2 restoration in human colonic adenocarcinoma cell 
line HCT8, induced cell cycle arrest and apoptotic death following propionate 
treatment- suggesting the tumour suppressor role of FFAR2 in cancer (Tang, 
Chen et al. 2011). 
In the recent studies the tumour suppressor function of FFAR2 was revisited. 
Leukemic mice manifested high propionate levels in vein upon the application 
of Inulin type fructans (ITF) – the indigestible carbohydrates, without 
modifying other common SCFAs, thereby reducing the accumulation of 
leukemia cells. Also in vitro studies showed that leukemic cell proliferation was 
decreased after propionate treatment by a cAMP level dependent mechanism. 
In addition to that it was also shown that another FFAR2 agonist (derivative of 
phenylacetamide) reduced proliferation of leukemic cells (Bindels, Porporato et 
al. 2012). However, proliferative role of FFAR2 is not well understood.  
FFAR2 and FFAR3 is found to be expressed in MCF7 breast cancer cell line. 
FFAR2 mRNA levels are notably exceeding than that of FFAR3. The same 
study revealed that FFAR2 and FFAR3 stimulation with propionate and acetate 
is aided through p38 mitogen-activated protein kinase (MAPK) / HSP27 
pathway  (Yonezawa, Kobayashi et al. 2007). Treatment with SCFAs on bovine 
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mammary epithelial cells (bMECs) was expected to induce ERK 
phosphorylation as SCFA is the major energy substrates for carnivores. 
Unexpectedly SCFAs was reported to be selectively activating p38 MAPK and 
not ERK. However, ERK phosphorylation upon FFAR2 stimulation with SCFA 
was observed in a study by Seljeset et al (Seljeset and Siehler 2012).  
FFAR3 is shown to aid tumor suppressor functions. One of the natural and 
potent ligand for FFAR3, butyrate has been found to cause an inhibition of the 
enzyme histone deactylase (HDAC). The resulting hyper acetylation of histones 
have led a numerous biological effects such as proliferation impediment, 
apoptosis and stimulation of cell cycle arrest (Wu, Zhou et al. 2012). Also, 
FFAR3 have been reported to modulate cell death in human breast cancer cells 
as well as H9c2 cells. Studies have demonstrated that during ischemic hypoxia, 
FFAR3 induces apoptosis through the p53/Bax pathway (Kimura, Mizukami et 
al. 2001). Various studies have proven the effects of butyrate-mediated 
inhibition of growth and proliferation by inhibiting HDAC activity. Other 
reports have explained the process behind this effect, like increased p21, a 
cyclin dependent kinase inhibitor levels. Besides cell cycle arrest, numerous 
classes of HDAC inhibition have been shown to manage gene expression of 
anti-apoptotic protein, Bcl-XL. In addition, there are recent evidence showing 
butyrate induced apoptosis by down-regulating Bcl-2 and up-regulating Bax and 
Bad (Tang, Yan et al. 2013). Since butyrate seems to be regulating apoptosis 
and proliferation and it has high affinity for FFAR3, it is possible that butyrate 
may be exerting these anti-tumor effects through activation of FFAR3 
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The number of studies focussing on the functions of FFAR2 and FFAR3 in 
cancer- related modulations is not many. More comprehensive studies are 
required to discern potential role of FFAR2 and FFAR3 in tumorigenic aspects. 
 
1.4.2 Long chain fatty Acids (LCFA) and its association to cancer- A 
review on the role of FFAR1 in Cancer 
 
An emerging body of studies have proven an indispensable association of fatty 
acid with cancer. Specifically, dietary fatty acid is considered to be one of the 
significant predisposing factor of cancer, including breast cancer. LCFA is 
classified based on the saturation of carbon atoms, among which, especially, 
saturated fatty acids, trans fatty acids and monounsaturated fatty acids are 
potentially related to increased cancer risk in humans (Chajes, Thiebaut et al. 
2008) and mouse models (Fay, Freedman et al. 1997). Similarly, a few 
polyunsaturated fatty acids that is the major component of the western food such 
as omega-6 polyunsaturated fatty acids, linoleic acid have been studied to have 
cancer promoting effects (Fiorio Pla, Grange et al. 2008) (Horrocks and Yeo 
1999). On a contrary, n-3 PUFA can exert anti- cancer effects.  
Cell culture based studies have identified that saturated fatty acids, 
monounsaturated fatty acids n-6 PUFA support the cellular growth and 
proliferation (Fay, Freedman et al. 1997). N-6 PUFA such as linoleic acid, 
arachidonic acid is identified to enhance the tumor growth and early stages of 
angiogenesis in mammary glands (Olivo and Hilakivi-Clarke 2005). N-6 PUFA 
is positively connected to oncogene, HER2 expression levels, leading to 
increased tumor growth, as presented in 40% breast cancer cases (Menendez, 
Vazquez-Martin et al. 2006) (Yee, Young et al. 2005). One exception on MUFA 
family of fatty acids is oleic acid. It is demonstrated that oleic acid reduces 
	 43	
tumorigenic effects by inhibiting the HER2 enhanced expression. Moreover, 
diet with increased oleic acid content in the Mediterranean regions brags lower 
cancer risks (Simopoulos 2001). Nevertheless, there is evidence supporting the 
cancer effects of oleate in breast cancer. Oleate is demonstrated to improve the 
proliferation, whereas the Saturated Fatty Acid (SFA), palmitate (C16:0) 
induced apoptosis. A possible explanation for the differential effect of these two 
FFAs came from the surprising observation that oleate and palmitate 
respectively, increased and decreased phosphatidylinositol 3-kinase (PI3K) 
activity (Hardy, Langelier et al. 2000).    
On a contrary, n-3 PUFA (Caygill, Charlett et al. 1996), alpha-linoleic acid, 
including, EPA, DHA (two LCFAs obtained from the metabolism of alpha- 
linoleic acid) reduces breast carcinogenesis (Menendez, Lupu et al. 2005) 
(Senzaki, Iwamoto et al. 1998). Animal xenograft model carrying human breast 
cancer when fed with n-3 PUFA diet showed a 66% reduction in tumor 
progression (Hardman, Sun et al. 2005). In addition, fish oil which majorly 
consists of high concentrations of EPA, DHA and n-3 PUFA presents the similar 
trend as mentioned above (Bourre 2007) (Stoll 2002) (Rose, Connolly et al. 
1996). However, relatively fewer studies on animal models (Fay, Freedman et 
al. 1997) and humans (Kaizer, Boyd et al. 1989) (Terry, Rohan et al. 2003) 
demonstrate the tumor inhibitory role of the long chain fatty acids.     
On a broader view, increased fat intake is affiliated to cancer risk. International 
correlation studies found a positive association between breast cancer incidence 
and per capita fat intake (Armstrong and Doll 1975). A positive correlation 
between fat intake and breast cancer incidence was established in a 12 case 
control meta-analysis study in 1990 (Howe, Hirohata et al. 1990). In contrast, 
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no such correlation was studied by Hunter’s group in 1996 (Hunter, Spiegelman 
et al. 1996). Despite compelling evidence from international correlation studies, 
more rigorous investigations based on case-control, cohort, or prospective 
studies only returned modest or non-associations of total dietary fat with breast 
cancer (Prentice, Caan et al. 2006) (Sczaniecka, Brasky et al. 2012) (Smith-
Warner and Stampfer 2007). Part of the reason for this is the differential and 
opposing effects is due to the different fatty acids. For example, 
monounsaturated fatty acids are significantly associated with increased breast 
cancer incidence (hazard ratio = 1.61), while omega-3 polyunsaturated fatty 
acids (n-3 PUFA) appear to protect against breast cancer. The understanding 
regarding other types of fatty acids is less clear. (Fay, Freedman et al. 1997) 
(Saadatian-Elahi, Norat et al. 2004) (Sczaniecka, Brasky et al. 2012).  
The effects of other fatty acids on breast cancer, including saturated fatty acid, 
MUFA and SCFA in human studies are also limited. As demonstrated here, not 
all unsaturated fatty acids prevent breast cancer and not all saturated fatty acids 
promote breast cancer. As a whole, omega-6 fatty acids (LCFA) appear to 
promote carcinogenesis whereas the Short chain fatty acids and omega-3 fatty 
acids (LCFA) are non-carcinogenic. As for the saturated fatty acids, the role in 
breast cancer development is dependent on the nature of individual fatty acids 
studied.  
1.4.2.1 Functions of FFAR1 in cancer 
 
In 2004, the first demonstration of FFAR1 mRNA in human breast cancer cell 
lines was presented by Yonezawa (Yonezawa, Katoh et al. 2004). The study 
investigated oleate- and linoleate- mediated upregulation of intracellular 
calcium levels which was partially abrogated by PTX. Another study in 2005 
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which involves mouse tumor xenograft model perfused in situ manifests 
hindered proliferation of MCF-7 cells treated with n-3 fatty acid EPA (Sauer, 
Dauchy et al. 2005). However, another report identifies, 100uM of oleate 
administered to MDA-MB-231 cells, stimulated cell growth which was 
inhibited by application of PTX (Hardy, St-Onge et al. 2005). The same group 
of authors in addition, implicated the expression of FFAR1 in MDA-MB-231, 
T47D and MCF-7 cells, whereby knocking down FFAR1 in MDA-MB-231 
cells, the proliferation was greatly reduced with the peak effect of oleate- 
induced response observed at 1 and 5 µM (Hardy, St-Onge et al. 2005). Two 
more studies published in 2008, identified the expression of FFAR1 and FFAR4 
in breast cancer cells, the expression of FFAR1 and FFAR4 was determined in 
MCF-7 and MCF-10A cells by flow-cytometry technique making use of anti-
receptor antibodies (Soto-Guzman, Robledo et al. 2008), while the other report 
detected that 400 µM oleate amplified oleate-mediated DNA synthesis in MCF-
7 cells and not in the non-tumorigenic cell line MCF-10A (Navarro-Tito, 
Robledo et al. 2008). A study concerning the function of FFAR1 in melanoma 
shows that FFAR1 expression levels were much higher in melanoma cells 
compared to breast cancer cells, moreover, TAK-875, FFAR1 agonist mediated 
decline in cell numbers was significantly higher in melanoma than in MCF-7 
cells. FFAR1 is also shown to play a significant role in migration and invasion 
in fibrosarcoma cells, HT1080 (Ishii, Kitamura et al. 2016). Similar effect with 
respect to FFAR1 and FFAR4 in WB-F344 liver epithelial cells were published 
(Fukushima, Yamasaki et al. 2015).   
On the contrary to other evidence, FFAR1 expression was observed to be 
elevated in A2058, A375, and SKMel3, all melanoma cells. These cells 
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subjected to TAK-875, a selective agonist for FFAR1 and GW9508, an agonist 
for both FFAR1 and FFAR4 inhibited proliferation of melanoma cells (Nehra, 
Pan et al. 2014). LPA- or EGF- induced proliferation and migration is inhibited 
by EPA (natural ligand for FFAR1 & 4) and FFAR1 agonist in MCF-7 and 
MDA-MB-231 cells (Hopkins, Liu et al. 2016). The inhibitory effect of FFAR1 
is further supported by similar studies regarding the effects of n-3 fatty acid in 
breast cancer cells (Manna, Chakraborty et al. 2008) (Zou, Bellenger et al. 2013) 
(Xue, Wang et al. 2014) (Pogash, El-Bayoumy et al. 2015). Pancreatic cancer 
cells show reduced motility and colony formation by knocking down FFAR4, 
while opposing effects like increased motility, MMP-2 activity and colony 
formation was observed in cells lacking FFAR1 expression (Fukushima, 
Yamasaki et al. 2015). About 80% of high-grade ovarian cancer carcinomas 
have indicated FFAR1 expression (Munkarah, Mert et al. 2016). They exposed 
ID8, A2780, C200, OVCAR3, and SKOV3 human ovarian cancer cell lines to 
a source of FFA resulting in increased FFAR1 expression. In addition, FFAR1 
and FFAR4 expression is detected in human prostate cancer cells, PC-3 and 
DU145. (Liu, Wang et al. 2015). 
The number of studies focusing on the role of FFAR1 in cancer is gaining 
attention when compared to the other FFARs members, however, there is no 
clear understading of the mechanism underlying the cellular events. From the 
available knowledge, it is evident that fatty acids play an imperative part in 
regulating cancer mechanisms. Nevertheless, the mechanism of action of 
different types of fatty acid in regulating cancer pathways is disputed. Thereby, 
opening windows for further investigation so as to serve a better curative option. 
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Figure 11 demonstrates an overview of all 3 FFARs- physiological function in 
various parts of the body.  
           
Figure 11: Physiological functions of FFARs at various sites of the human 
body (Miyamoto, Hasegawa et al. 2016) 
	 																																																																												 
1.5 An introduction to certain Cancer-related processes studied in this 
project 
 
In order to investigate the possible involvement of FFARs in breast cancer 
development, our study focused on a few significant aspects of cancer 
development such as, tumor proliferation, metastasis and autophagy.  
 
1.5.1 Tumor proliferation via common proliferative pathways 
 
1.5.1.1 Extracellular-signal-regulated kinase (ERK) pathway 
 
The ERK pathway transmits signals from cellular membrane receptors to 
transcriptional factors, regulating gene expression. Based on the exogenous 
stimulus and cell type, activation of this pathway can either lead to induction or 
inhibition of proliferation or apoptosis. Studies have shown that in human 
cancers, some of the proteins in this pathway are either mutated or abnormally 
expressed. In over half of all acute lymphocytic leukemia and myelogenous 
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leukemia cases, this ERK pathway has been shown to be activated and can be 
activated in breast cancer as well (McCubrey, Steelman et al. 2007). However, 
when activated in different cell lineage, different or even opposing effects can 
be observed. For example, ERK pathway is linked with drug resistance and 
cellular proliferation in hematopoietic cells whereas in some prostate cancer cell 
lines, this ERK pathway may be inhibited (McCubrey, Steelman et al. 2007).  
The relationship between GPCRs and MAPK pathway is well established. There 
are three major MAPK kinases in mammalian cells- ERK, P38MAPK and c-
JUN. GPCRs are shown to activate MAPK through several discrete mechanisms 
– by β-arrestin- dependent endocytosis pathway, Transactivation of RTKs or by 
the cellular second messengers (Luttrell 2002) (Figure 12). A study has shown 
that neurokinin 1 receptor- (NK1-) dependent activation of β-arrestin, mediates 
sustained ERK activation leading to nuclear translocation and subsequent 
proliferation of cells (DeFea, Vaughn et al. 2000). GPCRs can also activate 
ERK pathway, through the conventional heterotrimeric G protein effectors. Gi/o 
family G proteins mediate the MAPK regulation though Protein Kinase A 
(PKA). Gq/11 family G proteins induce the pathway in a PLC- intracellular Ca2+- 
PKC manner (Luttrell 2003). However, Gq/11 can mediate its effect in a PKC- 
independent way (Daub, Wallasch et al. 1997). GPCR-mediated transactivation 
of receptor tyrosine kinase (RTKs) is also shown to regulate MAPK pathway. 
For example, LPA promoted activation of MMPs can stimulate transactivation 
which goes on to initiate ERK activation (Schafer, Marg et al. 2004). Various 
studies have shown the GPCR-RTK transactivated ERK regulation as reviewed 
in Piiper’s publication in 2004 (Piiper and Zeuzem 2004).  
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Part of our study focuses on FFAR1-, FFAR2- and FFAR3- mediated regulation 
of this pathway in breast cancer development. 
    
Figure 12: An overview of GPCR-mediated- MAPK/ERK pathway. Adapted 
from (Rozengurt 2007). 
 
1.5.1.2 The Hippo-Yes associated protein (YAP) pathway 
 
The Hippo-YAP pathway is greatly involved in cellular growth signaling 
pathway that is gaining recognition in recent studies. This pathway involves the 
negative regulation of the activity of Yes-associated protein (YAP) and TAZ, 
which is the transcriptional co-activator of the pathway. These proteins are the 
two chief downstream regulators of the Hippo-YAP pathway. YAP and TAZ 
induce proliferation and inhibit apoptosis when the Hippo pathway is switched 
off, that is, phosphorylation of YAP does not occur, thus allowing YAP to 
localize into the nucleus. Kinases LATS1/2 are reported to inhibit YAP through 
phosphorylation at S127, resulting in YAP forming complex with 14-3-3 and 
ultimately lead to cytoplasmic retention or degradation (Dong, Feldmann et al. 
2007) (Figure 13).  
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Figure 13: Overview of Hippo-YAP pathway. A) When Hippo pathway is on 
MST1/MST2 phosphorylates SAV1, together they activate MOB1A/MOB1B, 
LATS1 and LATS2, which further phosphorylates and inactivates YAP 
protein and transcriptional coactivator TAZ. Phosphorylated YAP and TAZ 
are sequestered in the cytoplasm by the 14-3-3 protein and undergoes protein 
degradation. B) When the Hippo pathway is off, the kinases MST1, MST2, 
LATS1 and LATS2 are inactive, so YAP and TAZ are not phosphorylated and 
instead accumulate in the nucleus where they displace VGL4 and form a 
complex with TEADs, which promotes the expression of target genes. Adopted 
from (Johnson and Halder 2014). 
	
A significant function of the Hippo-YAP pathway is to control organ size as 
well as cellular proliferation. In many human cancers, YAP and TAZ has been 
reported to be hyper activated (translocated into nucleus) (Wang, McPherson et 
al. 2011). Loss of MST and LATS kinase ( negative regulators of YAP) or YAP 
overexpression has been reported to induce overgrowth of tissue cells such as 
liver and heart (Dong, Feldmann et al. 2007). This is because, Hippo-YAP 
pathway when dysregulated, results in resistance to apoptotic signals and 
uncontrolled cell proliferation. YAP is also shown to be regulated by other 
factors other than core Hippo pathway kinase cascade. In recent years, various 
upstream modulators of YAP are identified, such as tight junctions, adhesion 
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molecules. For example, a study by Kim in 2011, shows that E Cadherin 
regulates contact inhibition of proliferation mediated by Hippo-signaling 
pathway (Kim, Koh et al. 2011). Another interesting finding determined the role 
of GPCRs in regulating the YAP activation (Figure 14). GPCRs signaling 
through Gα12/13-, Gαq/11-, Gαi/o- facilitates YAP trans localization to nucleus 
enabling signals towards cellular growth, however, GPCRs coupling to Gαs 
inhibits YAP activity (Yu, Zhao et al. 2012). 
The same study has identified that FFAR1 is involved in upregulating YAP 
signaling thus leading to increased cell growth signals.  
                          
Figure 14: An outline of GPCR-G protein- mediated Hippo-YAP regulation. 
A proposed model for GPCRs and G-proteins in the regulation of Lats and 
YAP/TAZ activities. We propose that Lats1/2 kinases are inhibited by 
G12/13-, Gq/11-, and Gi/o-coupled receptors and activated by Gs-coupled 
receptors. Moreover, Rho GTPases and actin cytoskeleton organization 




However, current research is still unable to identify the exact mechanism as to 
how YAP and TAZ regulate downstream signaling leading to proliferation and 
inhibition of apoptosis. Moreover, not much is known regarding the upstream 
mediators of YAP and TAZ apart from canonical Hippo pathway effectors 
(MST/ Nrf2/ LATS). Therefore, in this study, the roles of FFAR2 and FFAR3 
in mediating Hippo-YAP pathway signal was studied.  
         
1.5.2 Metastasis through EMT 
 
Metastasis is a process in which cells disperse from the primary tumor site to 
distant organs (Fidler 2003).  Despite decades of research on metastasis, along 
with significant medical advancements in cancer diagnosis and treatment, 
metastasis still accounts for 90% of all cancer deaths (Gupta and Massague 
2006). Patients with metastatic cancers are often unresponsive to traditional 
therapies. The main barrier to existing treatment of metastasis is the genetically-
diversified heterogeneous cancer cell population in the primary tumor and in 
metastases. This heterogeneity of tumor cells contain subpopulations exhibiting 
varying metastatic and angiogenic properties (Khan and Mukhtar 2010). This is 
because the genetic instability of tumor cells, it drives rapid biological 
diversification and heterogeneity. In addition, the metastatic cancer cells can 
behave in a certain way depending on the specific region or the environment it 
is present in, which also determines their response towards systemic therapy, 
because these metastatic cells can be located in lymph nodes and different 
organs (Steeg 2006). Thus, in order to better treat metastatic cancers, 
understanding the pathogenesis of metastasis is therefore, important in cancer 
research.  
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Metastasis is a complex multi-stage process involving invasion of tumor cells 
from primary site to intravasating into systemic transport and extravasation of 
the cells into circulatory system, and lastly initiating angiogenesis and growth 
at distant site (Chambers, Groom et al. 2002). In first step of metastasis, it 
involve the epithelial cancer cells to increase motility and degrade the 
underlying basement membrane and extracellular matrix (ECM) to initiate the 
escape from the primary site (Tsai and Yang 2013). It is hypothesized that the 
initiation of metastasis involves the process known as Epithelial-Mesenchymal 
Transition (EMT). 
 
1.5.2.1 Epithelial-Mesenchymal Transition (EMT) 
 
EMT is a process where the epithelial tumor switch from a differentiated, 
adherent phenotype to a potentially pluripotent, individual, invasive 
mesenchymal cell (Zeisberg and Neilson 2009). The process is mainly 
characterized by downregulation or loss of cell junction proteins, together with 
structural changes that lead to the loss of cell–cell adhesion and apical-basal 
polarity, eventually resulting in epithelial cells acquiring mesenchymal features, 
such as spindle shape and increased invasive and migratory ability (Kalluri and 
Weinberg 2009) (Figure 15). EMT is not only critical for normal physiological 
processes, such as embryogenesis but also involved in pathological processes, 
for example wound healing and renal fibrosis.   
A study designed the reversible EMT metastasis model where primary epithelial 
cancer cells acquired the ability to invade and spread throughout the body 
through the activation of EMT, whereby, reaching far-off organs the cancer cells 
go through a reverse procedure which is mesenchymal-epithelial transition 
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(MET) to form epithelial metastases (Thiery 2002). This interesting proposal 
has sparked interest in idea of how EMT can be involved in carcinoma 
metastasis.  
Due to extensive research, many of the hallmark EMT effector molecules have 
been identified. These EMT effectors are usually subcellular structure proteins 
that define mesenchymal or epithelial phenotype in a cell. These proteins can 
be bound to different stages of regulation during EMT. For instance, the genes 
for the cell junction proteins, such as γ-catenin, α-catenin and E-cadherin are 
downregulated at the transcriptional and mRNA levels. E-cadherin is known to 
be the doorkeeper of the epithelial phenotype in multiple epithelial cell types. 
Loss of E- Cadherin leads to the loss of ability to maintain cell-cell adhesion 
and cellular integrity, thus promoting epithelial tumors to undergo metastasis 
(Birchmeier and Behrens 1994). It is reported that during EMT, E-Cadherin is 
subjected to various levels of regulation. Suppression of the E-Cadherin gene 
transcription (Batlle, Sancho et al. 2000), promoter methylation (Graff, Herman 
et al. 1995), and protein phosphorylation and degradation (Zhou, Deng et al. 
2004) have been perceived in reaction to EMT-stimulating signals. 
Furthermore, during EMT, intermediate filaments (IF) are reported to 
interchange from cytokeratin, an epithelial IF protein, to vimentin, a 
mesenchymal IF protein. Upregulation of Vimentin is also a classical marker 
observed during multiple EMT events.  
Aberrant functioning of GPCR is linked to cancer progression and metastasis, 
there are evidence showing over-expressed GPCRs in several cancer types (Li, 
Huang et al. 2005). Organ-specific metastasis is mediated by over-expressed 
GPCRs, such as, chemokine receptors in cancer cells resulting in release of 
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chemokines from the secondary organs leading to cancer progression (Ben-
Baruch 2008). Among the well-studied GPCRs- LPA is shown to play a 
significant role in mediating invasion and migration in MCF-7 breast cancer 
cells (Wang, Sun et al. 2016).    
EMT plays a crucial role in cancer progression and GPCRs have been shown to 
play a role in modulating metastasis, the possible roles of FFAR1, FFAR2 and 
FFAR3 in regulating EMT was studied.  
      
Figure 15: Essential steps in the process of EMT 
The illustration demonstrates the essential stages involved in Epithelial-
mesenchymal transition. The diagram shows four key steps that are essential 
for the completion of the entire EMT course and the most commonly used 




Autophagy is a cell survival- inducing process. The process degrades cellular 
organelles in a lysosomal-dependent manner preventing toxin build-up and 
provides sustained metabolism under starvation condition (Mizushima and 
Komatsu 2011). Since autophagy process involves in providing nutrients and 
eliminating degraded proteins, it is reasonable to believe that it plays a 
protective role for cell survival. Deficiency in this essential process is expected 
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to have detrimental effects thus exacerbating conditions like liver disorders, 
neurodegenerative disease and cancer (Levine and Kroemer 2008). Autophagy, 
at physiological level is tissue-dependent, involving a complex mechanism, 
however in tumor environment autophagy is reported to either inhibit or 
promote cancer cell growth, implying the role of autophagy in cancer is context-
dependent (White 2012). LC3 is a ubiquitin-like protein, considered to be one 
of the most extensively inspected autophagy marker. LC3 is proteolytically 
cleaved to fetch LC3I which by the end is converted to 
phosphotidylethanolamine (PE) conjugated LC3II. LC3II-PE complex, the only 
protein marker that is reliably associated to autophagosomes, for the very reason 
LC3II is considered to be the traditional marker for autophagy study (Huang, 
Scott et al. 2000). In addition to LC3, p62 protein also called as sequestosome 
(SQSTM1) is ubiquitin- binding scaffold protein, which is identified to directly 
bind to LC3 serving as a link between polyubiquitinated proteins and LC3II 
(Bjorkoy, Lamark et al. 2005) (Figure 16). Any repression in autophagy process, 
an increased accumulation of p62 is observed in mammals and drosophila, thus 
reflecting the autophagy status (Bartlett, Isakson et al. 2011) (Lee, Yu et al. 
2010).  
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Figure 16: Mechanism of autophagy regulation involving LC3 and p62    
Autophagy is critical in maintaining cellular homeostasis, any deregulation 
in its signaling leads to pathological conditions. Ubiquitylation of protein 
aggregates is a signal that triggers binding of the adaptor proteins p62, which 
also binds light chain 3 (LC3; the mammalian homologue of autophagy 
protein 8 (Atg8)) conjugated with lipids in the double membrane of the 
forming autophagosome. This allows cargo to be included in the forming 
autophagosome, which subsequently fuses with lysosomal compartments to 
release its inner-membrane vesicle with included cargo for hydrolytic cargo 
degradation. (Tyedmers, Mogk et al. 2010) 
      
From the earlier reports it is derived that autophagy process is tumor- 
suppressor, as 40 to 75% of human breast and prostate cancer is manifested for 
lack ATG6/BECN1 (Choi, Ryter et al. 2013) (Liang, Jackson et al. 1999). 
Autophagy deficiency can also induce DNA damage through oxidative stress 
and genomic instability thus leading to enhanced cancer growth (Vogelstein, 
Papadopoulos et al. 2013). Nonetheless, tumors can also depend on autophagy. 
In hypoxic tumorous conditions, autophagy helps provide a survival 
environment for the cells (Guo, Chen et al. 2011). Ras-driven cancer cells 
maintain enhanced autophagy to promote cell survival and growth (Lock, Roy 
et al. 2011) (Guo, Xia et al. 2013) (Figure 17).  
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Figure 17: Role of autophagy in tumor promotion and suppression 
(A) Proposed mechanisms by which autophagy may suppress tumorigenesis. 
Autophagy defects impair tissue health, leading to chronic tissue damage and 
regeneration that may create an environment that promotes cancer. (B) 
Proposed mechanisms by which autophagy promotes cancer by limiting stress 
responses and supporting metabolism and survival. (White 2015). 
 
Free fatty acids are shown to be modulating autophagy. FFA are shown to 
induce autophagy in pancreatic ß cells as a safety mechanism avoiding apoptosis 
during high FFA concentration and insulin-resistant state (Ebato, Uchida et al. 
2008). Additionally, a study by Choi et al, FFA was investigated for its function 
in converting LC3I to LC3II along with autolysosome formation in ß cells, they 
concluded that FFA induce autophagy (Choi, Lee et al. 2009). Similarly, 
palmitate but not oleate induce autophagy in hepatocytes via JNK2 (Tu, Zheng 
et al. 2014). On the contrary, oleate and palmitate possess altering functions in 
autophagy, oleate induces autophagy, however palmitate induced apoptosis 
rather than autophagy in HepG2 cells (Mei, Ni et al. 2011). According to a 
recent finding, both oleate and palmitate induces autophagy, where palmitate 
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mediates the effect through AMPK- JNK1 and BECN1 complex, on the other 
hand, oleate requires intact golgi apparatus, involving non canonical pathway in 
facilitating autophagy  (Niso-Santano, Malik et al. 2015). Therefore, it is clearly 
comprehended from above findings that FFA mediated autophagy is still an 
unanswered question. On the basis of which, we intended to study the role of 
FFAR1 in mediating palmitate- & oleate- dependent autophagy effects in breast 
cancer cells.   
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1.6 Hypothesis and Aims  
 
Various in vitro, in vivo and epidemiological studies have identified a 
correlation between dietary fatty acid and risk factors of breast cancer. 
However, contrasting roles of LCFA and SCFA in regulation of breast cancer 
is studied. Following the discovery of free fatty acid receptors (FFARs), the 
function of these receptors in mediating fatty acid stimulated signaling cascades 
in breast cancer studies has started gaining attention. The literature evidence led 
us to hypothesize that  
Hypothesis 1: FFAR2 and FFAR3 signaling short chain fatty acid, facilitates 
tumor- inhibiting pathways in breast cancer by inhibiting the regulators of 
crucial proliferative- and EMT-pathways. 
 
Hypothesis 2: Excessively stimulated FFAR1 by long chain free fatty acids 
results in the activation of tumor promoting pathways. 
Aims: 
Ø Expression profiling of FFARs in breast cancer cell lines  
Ø Engineering cells to over-express the receptors of interest 
Ø Characterization of pro-tumorigenic processes mediated by free fatty 
acids- FFARs 
Specific objectives: 
Ø Investigate the potential effectors of cell proliferative pathway- ERK 
and Hippo-YAP. 






























Primary antibodies: E-cadherin (CST #3195), p44/42 MAPK (CST #9102), 
Phospho- p44/42 MAPK (CST #9101), p38MAPK, β-actin antibody (Sigma #A 
5316), V5 tag antibody (ThermoFisher Scientific #R960-25), total YAP 
antibody (Santa Cruz # G2710), pYAP (CST #4911S), vimentin (CST #5741S), 
FAK (CST #3285S), LATS1 (CST #3477S), LAT2 (CST#5888S), LC3B 
(CST#2775S) and p62 (CST #5114S). Secondary antibodies: Horseradish 
peroxidase- conjugated goat anti-rabbit (CST #7074) and anti-mouse (CST 
#7076), Alexa Fluor 594 (ThermoFisher Scientific #A-11005) and Alexa Fluor 
488 phalloidin (ThermoFisher Scientific #A12379).  
Propionate (propionic acid # 402907) from Sigma-Aldrich Corporation. Oleate 
(oleic acid #O1008-1G) from Sigma-Aldrich and Palmitate (Palmitic acid # 
P0500) from Sigma, essentially fatty acid-free bovine serum albumin (FAF-
BSA) obtained from Sigma-Aldrich Corporation. GW9508 (#CAS 885101-89-
3) and GW1100 (#CAS306974-70-9) were obtained from Cayman Chemical. 
BrdU from Invitrogen (#000103). DAPI from Sigma (#D9542). Chloroquine 
from Sigma (#C6628). MTT powder from Sigma (# M5655). Geneticin by 
Gibco (# 10131-035), Westernbright Sirius detection kit from Advansta (# 
141104-94), Collagen Type I from Millipore (08-115),  
2.1.2 Cell lines culture and ligand preparation and treatment 
 
Human breast cancer cell lines- MDA-MB-231, MCF-7 and Human embryonic 
kidney cells (HEK-293), human breast epithelial non-tumorigenic cell line 
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(MCF-10A), human mammary epithelial cell line (HCC1569) were obtained 
from American Type Culture Collection (ATCC). Cells were cultured as 
monolayers in complete media and incubated in humidified incubators with 
optimal conditions at 370C with 5% carbon dioxide. Contents of the complete 
media were as following: Hyclone DMEM containing 4mM L-glutamine, 
4500mg/L glucose and without sodium pyruvate (Thermo Scientific); 
supplemented with 10% fetal bovine serum (Thermo Scientific), 1% L-
glutamine (GE Healthcare Life Sciences) and 1% penicillin/streptomycin 
(Invitrogen).  
Propionate, the ligand used for FFAR2 and FFAR3 experiments, was diluted 
from a 100mM stock solution with 100% absolute ethanol. Propionate was then 
diluted 1/100 with DMEM to the final working concentration of 1mM just 
before each experiment. As for vehicle treatment, 100% absolute ethanol was 
used and diluted with DMEM to 0.1% final working concentration. FFAR1 
ligand, oleate and palmitate was maintained as a 100mM stock solution in 
ethanol. Immediately before use, both faty acid were diluted 1:10 with 10% fatty 
acid-free bovine serum albumin (FAF-BSA), then further diluted with DMEM 
to final working concentrations. The control treatment consisted of ethanol and 
FAF-BSA in the same concentrations as in the oleate/palmitate treatment. Other 
ligands 10 μM GW1100, 1 μM GW9508 and 0.1μg/mL EGF were diluted in 
DMEM to final working concentrations.  
For assays not involving ligand treatment, cells were assayed directly. For 
assays involving ligand treatment, cells were serum starved for 4 hours prior to 
ligand treatment. After which, the treatment conditions were applied as stated 
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in each respective assay.  
2.2 Methods 
	
2.2.1 Generation of vector control, FFAR2 and FFAR3 overexpression 
stable cell lines in MCF-7 and MDA-MB-231  
 
Two types of breast cancer cell lines were used: MCF-7 and MDA-MB-231. 
FFAR2/FFAR3 gene (AITbiotech) was first ligated in pcDNA3.1 /V5-His 
TOPO mammalian expression vector (Invitrogen) (Figure 18). The V5-tagged 
FFAR2/FFAR3 plasmid was then linearized with PvuI (New England Biolabs). 
Next, Transfection of the linearized plasmid into MCF-7 cells was done using 
Lipofectamine 3000 (Invitrogen). Transfected cells were then treated with 
Giboco® Geneticin® Selective Antibiotic (Life Technologies) at a 
concentration of 1mg/ML for two weeks. An additional well was seeded with 
wild type MCF-7 cells and undergo same Geneticin® treatment to serve as a 
negative control for the selection. Since the plasmid contained neomycin 
resistance gene, those successfully transfected cells would have taken up the 
plasmid and gain resistance against Geneticin®. Thus, those Geneticin® -
resistant cells were selected for. Selection was terminated once complete cell 
death was observed in the negative control well. Those Geneticin® -resistant 
cells were then cultured onto a plate and maintained as FFAR2/FFAR3 
overexpression stable population cell line. 
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Figure 18: pcDNA3.1/V5-His-TOPO mammalian expression vector map 
2.2.2 MTT Viability Assay 
 
Semi-confluent cells were seeded onto 96-well flat bottom plate. Following 
treatment (if any), yellow MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide, a tetrazole) (Sigma-Aldrich) was added to each 
well to a final concentration of 0.5mg/mL. Cells were then incubated at 370C 
for 2hrs. During the incubation, presence of mitochondrial dehydrogenase of 
viable living cells would reduce the MTT to insoluble purple formazan crystals. 
The media with yellow MTT was then aspirated and MTT solvent (4mM HCL/ 
0.1% Nondet P-40 (NP40) in isopropanol) was added to solubilize the MTT 
crystals. The plate was then covered with foil and incubated on shaker for 
20mins. Lastly, the absorbance was being read at 590 nm, using Tecan Safire2 
Microplate Reader.  
To test chemotherapeutic drug resistance, Equal number of cells were seeded 




four hours, followed by drug and ligand treatment. All cells were treated at 1mM 
propionate. Three different chemotherapy drugs were used: Doxorubicin, 
Cisplatin and Paclitaxel. Highest concentration of each drug is different as 
shown below (Table 5). Serial dilutions of the drug were done from the highest 
concentration and a total of 10 different concentrations of the same drug were 
obtained. Six replicates were set up for each of the 10 concentrations. The cells 
were subjected to propionate and drug treatment and incubated for 72 hours 
before MTT assay was performed.  














2.2.3 Wound-Healing Assay 
 
Confluent MDA-MB-231 cells were starved and treated as indicated. Next, cells 
were scratch-wounded using a sterile 200μl pipette tip, washed twice with 
DMEM to remove suspended cells and re-fed with DMEM supplemented with 
1% FBS and the treatment ligands. The progress of cell migration into the 
wound was photographed at different times using an inverted microscope 
coupled to a camera. Image J software was used to quantitate the area of the 
wound that was uncovered with cells.  






2.2.4 Matrigel Invasion Assay 
 
Invasiveness of MDA-MB-231 stable cell population was measured by Biocoat 
Matrigel cell invasion assay (Corning) according to the manufacturer’s 
instruction. Briefly, matrigel matrix coated at the bottom of transwell insert was 
reconstituted by adding DMEM into both insert and well and incubation at 37oC 
for 2hrs. 2 x 105 cells were seeded in DMEM in the insert and incubated 
overnight. DMEM in well was replaced with DMEM containing 10% fetal 
bovine serum. 1mM propionate or vehicle control was added to the insert. After 
24hrs, cells invaded to the other side of the membrane at the bottom of the insert 
were fixed with methanol and stained with crystal violet. The invaded cells were 
counted manually under the microscope at 20X magnification using ImageJ 
(NIH). Four fields were counted for each insert.  
2.2.5 BrdU Proliferation assay 
 
Cells were seeded on collagen (Millipore #08-115) coated cover-slips. Next 
day, the cells were incubated with BrdU (1:100) overnight, typically 
simultaneous with ligand treatment. Next the cells were fixed in 70% ethanol 
for 30 minutes. DNA denaturation using 0.1N HCL/0.5% triton-X 100 for 10 
minutes, then washed with PBS. The cells were blocked for atleast 30 minutes 
in 2.5% BSA. The cells were washed with 1X PBS between each step. Then 
Incubate with primary antibody anti-BrdU at 1:50 dilution overnight @ 40C, 
after 3 washes incubated with secondary antibody for 2 hours at room 
temperature. Cells were counter stained with propidium iodide to obtain the 
total cell count, as DAPI does not work on denatured DNA. The cover slips 
were mounted on to a slide using vectashield and visualized under florescence 
microscopy. 
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2.2.6 Western Blot 
 
Cells were grown to confluence on 6-well plate, serum starved for 4hrs and 
treated under conditions as indicated. After treatment, media was aspirated, ice-
cold PBS was used to wash cells. PBS was removed, cell lysis buffer (1% Triton 
X-100/ 250mM NaCL / 0.5mM EGTA (Ethylene glycol tetraacetic acid) / 2mM 
EDTA (Ethylenediaminetetraacetic acid) / phosphatase and protease inhibitors 
(Roche) / 20mM HEPES) was added. Cells were scraped, transferred to 
microcentrifuge tubes and maintained at constant agitation on ice for 30mins. 
Cell suspension were centrifuged at 13,500 rcf for 15 minutes at 40C. 
Supernatant was collected and transferred to fresh Eppendorf tubes. Protein 
concentration was quantified using Bradford protein assay (Bio-Rad). Using 
measured protein concentration, 3 parts of sample was diluted with 1 part of 4X 
SDS-loading dye and then denatured at 980C for 10 minutes. For SDS PAGE 
gel, 10% resolving gel and 4% stacking gel were used. For detection of ERK, 
YAP, 15ug of samples for LATS1/2 and E-cadherin 30ug of samples were 
loaded. However, for detection of E-cadherin expression in MCF-7, only 5ug of 
samples were loaded due to high endogenous E-cadherin expression. Gel was 
ra n at 80V for 30 minutes and then increased to 110V for another 1 and half 
hours. Separated proteins were then transferred onto the methanol-activated 
polyvinylidene fluoride (PVDF) membrane (Bio-Rad) via the wet transfer 
method at 100V, 0.2A for 1.5hrs. The membrane was briefly rinsed in Tris-
Buffered Saline with Tween 20 (TBST) (50mM Tris-HCL, 150mM NaCL at 
pH8, 0.1% Tween 20) and then incubated in blocking buffer (5% non-fat milk 
in TBST) with constant agitation for 2hrs. Membrane was then washed with 
1xTBST, incubated with respective primary antibody overnight at 40C, washed 
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and incubated with HRP-conjugated secondary antibody for another 2 hours. 
All primary antibodies, except beta (β)-actin antibody, were diluted 1,000-fold 
with dilution buffer (5% BSA in TBST). All secondary antibody, except 
secondary antibody for β-actin, were diluted 5,000-fold with dilution buffer. 
Both primary and secondary antibody for β-actin were diluted 10,000-fold with 
dilution buffer. To visualize the protein bands, membrane was exposed to 
chemiluminescent WesternBright Sirius HRP substrate (Advansta). 
Quantification of protein bands, based on size and intensity, was done using 
GelPro application. For all the proteins studied, the cells were serum starved for 
4 hours, followed by ligand treatment for 4 hours for E Cadherin, Vimentin, 
FAK, YAP and LATS. For ERK the cells were treated for 5 minutes. 
2.2.7 Quantitative reverse transcription PCR (qPCR) 
 
RNA was isolated from confluent cells using TRIzol (Invitrogen) and then 
converted to cDNA via the cDNA Reverse Transcription Kit (Applied 
Biosciences). Primers used for qRT-PCR are listed in Table 4. Quantitative PCR 
using SYBR Green (Thermo Scientific) was carried out via a series of steps: 
950C for 10 minutes, followed by 40 cycles of 950C for 15 seconds and 600C for 
1 minute.  
Table 5: Primers used in qRT-PCR 
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Prior to cell seeding, ethanol-washed coverslips were coated with 1% Collagen 
Type I (Millipore). Cells were then seeded at semi-confluent density onto the 
coverslips and incubated overnight. After which, the cells were fixed with 4% 
paraformaldehyde (PFA), washed with 1x phosphate-buffered saline(PBS) and 
then blocked in blocking buffer (2.5% Bovine Serum Albumin(BSA) from 
Sigma / PBS / 0.3% Triton X-100) for 1.5hrs. Cells were then incubated in 
primary antibody (1:1000 in blocking buffer) for 3hrs, washed with 1X PBS, 
followed by incubation with secondary antibody (1:500 in blocking buffer) for 
1.5hrs and washed with 1X PBS. Lastly, cells were then incubated in 4’, 6-
Diamidino-2-phenylindole dihydrochlotride (DAPI) solution (Sigma-Aldrich, 
1:1000 in PBS) for 7 minutes. Coverslips were then transferred on to a polysine 
slide (Thermo Fisher) using Vectashield (Vector laboratories) and visualized 
under a fluorescence microscope.  
To validate stable FFAR2 and FFAR3 over-expression cells lines, the cells were 
directly harvested and assayed without any treatment. Primary antibody used 
was V5 antibody (Invitrogen), while the secondary antibody used was Alexa 
Fluor-594 anti-mouse antibody (Invitrogen). Dilution factor for the antibodies 
were as indicated above. For vimentin ICC, the cells were treated with 1mM 
propionate for 4 hours. Secondary antibody used for vimentin protein is 488 




2.2.9Cyclic AMP (cAMP) ELISA assay 
 
Cells were seeded at semi-confluent density in 24-well plate, serum starved for 
4 hours, followed by treatment under conditions as indicated for 5 mins. 
Forskolin (FSK) / 3- isobutyl-1-methylxanthine (IBMX) solution was prepared 
for stimulation of Gai/o-coupled receptors. Stock solution for FSK was 10mM in 
Dimethyl sulfoxide (DMSO) and for IBMX was 500mM in DMSO. FSK/IBMX 
solution was prepared by diluting with DMEM. The FSK/IBMX solution was 
added to the wells with final concentrations of 0.5mM IBMX and 5μM FSK 
(for MCF-7) or 25μM FSK (for MDA-MB-231) and incubate at 370C for 
15mins. Media was aspirated completely, 0.1M HCL was added and incubated 
for 20mins on shaker. Using cell scrapers, cells were dislodged and transferred 
to Eppendorf tubes. Cell lysate was then centrifuged at 1,000 rcf for 10mins. 
The supernatant was then transferred to a fresh Eppendorf tube and assayed 
according to the protocol from Cayman Cyclic AMP EIA Kit. The cAMP 
standard curve was also prepared using the same protocol. After overnight 
incubation at 40C, the plate was developed by adding fresh Ellman’s reagent and 
incubate for 1hr. The absorbance was then read at a wavelength of 415 nm.  
2.2.10 Phalloidin labelling 
 
Cells were plated on 1% collagen-coated coverslips, fixed with 4% 
paraformaldehyde, the cells were permeabilised with 0.3% Triton-X-100 in PBS 
for 30 minutes and the cells were blocked with 0.1% BSA diluted in 1x PBS for 
20 minutes, in between the steps the cells were washed with 1x PBS. Then cells 
were incubated in rhodopsin phalloidin (1:250) (Invitrogen) for 1 hour. Next the 
coverslips were washed with PBS and incubated with DAPI for 5 to 7 minutes 
after subsequent washes, the coverslips were mounted onto a slide using 
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vectashield and visualized under fluorescence microscopy.  
2.2.11 TGFα shedding assay 
 
Upon stimulation of a ligand, an activated GPCR induces TACE-dependent 
cleavage, known as ectodomain shedding, and release of membrane-bound pro-
AP-TGFα. Released AP-TGFα can be quantified by measuring alkaline 
phosphatase (AP) activity in the conditioned medium based on the production 
of yellow-colored p-NP from p-NPP. HEK293 cells were seeded in a 6-well 
plate and transfected with AP-TGFα and FFAR1, FFAR2 and FFAR3 plasmids 
using Lipofectamine 2000 (Life Technologies) according to the manufacturer’s 
instruction. After 24h incubation, transfected cells were re-seeded in 96-well 
plate in Hank’s Balanced Saline Solution  
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Figure 19: Mechanism of TGF-α shedding assay HEK293 cells that 
transiently express pro-AP-TGFα with or without a GPCR were reseeded in 
a 96-well plate and stimulated with a ligand. After conditioned medium was 
transferred into a blank plate, AP-TGFα release was quantified by 
colorimetric reaction of AP using p-NPP as a substrate. (Inoue, Ishiguro et 
al. 2012) 
 
(HBSS) and incubated for 30min. Receptor antagonist was added and incubated 
for 15min where applicable, followed by 1hr incubation with agonist. The 
conditioned media was then transferred to another 96-well plate after 
centrifugation at 190xg for 2min. Both plates were incubated with p-NPP 
solution for 1hr at 37°C. Optical density at 405nm was measured at 15min and 
1hr 15min after p-NPP addition using a microplate reader and Magellan 
(Tecan). The difference between two measurements was a measure of AP-
TGFα release, reflecting the level of FFAR activation (Figure 19). 
2.2.12 Statistical analysis 
 
All quantitative data are presented as mean ± standard deviation (SD) obtained 
from independent experiments. Experiments were carried out with 3 or more 
replicates. To analyze the significance between two groups, two-tailed Students 




















Chapter 3- Results (Part I) 
3.1 FFAR2 and FFAR3 promotes anti-tumorigenesis pathways 
	
3.1.1 Low endogenous expression of FFAR2 and FFAR3 in MCF-7 and 
MDA-MB-231 
 
Initially, FFAR2 and FFAR3 expression was characterized in a panel of breast 
cancer cell using qRT-PCR. Amongst the cell lines tested MCF-7 and MDA-
MB-231 cells were selected as our study model, as MCF-7 and MDA-MB-231 
cells show relatively low endogenous expression of the receptors (Figure 20). 
Moreover, these cell types are of different phenotypic nature, MCF-7 more like 
an epithelial cell line and MDA-MB-231 is more like a mesenchymal cell line.  
          
Figure 20: MCF-7 and MDA-MB-231 expresses low levels of FFAR2 & 
FFAR3 
	
Qualitative PCR (qPCR) was performed in a panel of breast cancer cells for 
their endogenous expression of FFAR2 and FFAR3. GAPDH is used as the 
house-keeping gene. The expression levels were normalized to MCF-7 cells. 
The result shown is an average of 3 independent experiments, N=3. 
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3.1.2 Engineer and validate the over-expression of FFAR2 and FFAR3 in 
MCF-7 & MDA-MB-231 cells 
 
The pcdna3.1/V5-His-TOPO vector was utilized for the over-expression of 
FFAR2 or FFAR3 in MCF-7 and MDA-MB-231 cells as mentioned in section 
2.2.1.  
To test the functionality of the receptors, FFAR2 inserted into pcDNA3.1/V5-
His-TOPO & FFAR3 inserted into pcDNA3.1/V5-His-TOPO vector at multiple 
cloning site was transiently transfected into HEK293 cells for validation. 
Immunocytochemistry against V5 epitope tag showed membrane labelling in 
untreated cells, which internalized upon ligand treatment (Figure 21 A).  
Generation of over-expression cells: Upon testing the receptor constructs, the 
constructs were further utilized to generate over-expression system. The 2 cells 
lines, MCF-7 and MDA-MB-231 found to have low expression for both FFAR2 
and FFAR3 selected from the screen were used for the generation of over-
expression cells. The transfected cells were selected for the stable over-
expression by growing them in Geneticin containing media, because the vector 
consists of neomycin resistant gene. Thereby totally 6 cell lines were generated 
MCF-7 pcDNA3.1, MCF-7 FFAR2, MCF-7 FFAR3, MDA-MB-231 
pcDNA3.1, MDA-MB-231 FFAR2 and MDA-MB-231 FFAR3. 
Immunocytochemistry (ICC) was further used to validate FFAR2 and FFAR3 
overexpression cells and results were as demonstrated in Figure 21 B. All six 
engineered cell lines were labelled with V5 and nuclei stain DAPI. The FFAR2 
and FFAR3 overexpressed cells were clearly membrane-labelled in both MCF-
7 and MDA- MB-231 cells while in pcDNA3.1 vector control there is no V5 
labelling. Furthermore, a qPCR was performed to test the receptor over-
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expression in our cellular systems- MCF7 (Figure 21 C) and MDA-MB-231 
(Figure 21 D). Thus, both qRT-PCR and ICC results validated that the MCF-7 
and MDA-MB-231 overexpresses FFAR2 and FFAR3.              
                      
 





























                 
Figure 21: Over-expression of FFAR2 & FFAR3 was established in MCF-7 
and MDA-MB-231 
A) Immunocytochemistry V5- labelling in HEK293 cells transiently transfected 
with FFAR2 and FFAR3. The cells were subjected to 4hrs serum starvation and 
then stimulated with 1mM propionate (treated group) or vehicle (untreated 
group) for 1 hour. B) Immunocytochemistry V5-labelling in MCF-7 and MDA-
MB-231 cells over-expressing FFAR1. Cells were subjected to 4hrs serum 
starvation and then stimulated with 1mM propionate for 1 hour C) 
Immunocytochemistry V5 staining in stably transfected MCF-7 and MDA-MB-
231 cells show the V5 staining in FFAR2 and FFAR3 over-expressed MCF and 
MDA-MB-231 cells. D) demonstrates the FFAR2 and FFAR3 mRNA 
expression levels in MCF-7 and MDA-MB-231 over-expression cells 
respectively. 
 
3.1.3 Short chain fatty acid, propionate, activates FFAR2 and FFAR3 
 
As mentioned in section 1.2.3, propionate, is a potent and the natural ligand 
which has equal potency in activating both FFAR2 and FFAR3 (Bain, Scott et 
al. 2013), therefore we selected propionate for our study. Here we demonstrated 
the activation of the receptors using the recently developed TGFα- shedding 
assay, which is a robust method to detect ligand mediated receptor activation. 
The principle behind is, upon stimulation of GPCR, ectodomain shedding of 
membrane-bound pro-AP-TGFa (reporter enzyme) occurs. This shedding is 
D
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measured in the conditioned media.  
HEK 293 cells transfected with FFAR2 and FFAR3 is shown to be activated by 
propionate (Figure 22 A & B respectively). The vector control treated with 
propionate does not display any detectable AP-TGFa shedding, demonstrating 
that this is a receptor-mediated response. Also, the graph denotes that Emax is 
obtained at 1mM concentration of propionate.  
                 
              
Figure 22: Propionate, the natural ligand activates FFAR2 & FFAR3 with 
equal potency                                                                      
The TGFα-shedding assay was performed to evaluate the activation of FFAR2 
and FFAR3 with the propionate. The graph here shows the shedding % of AP-
TGFɑ upon propionate stimulation in HEK293 cells transfected with FFAR2 & 
FFAR3- (A) & (B) respectively. The results shown are representative of 3 





3.1.4 Inhibition of cAMP production mediated by FFAR3  
 
cAMP assay was carried out on the over-expression cell system to validate 
functional activity of the stably expressed receptors. To ensure that the assay 
shows the receptor selectivity, a negative control, pcDNA3.1 vector was 
included. To demonstrate the basal intracellular cAMP level, to one of the 
vector control group, no FSK was added. MCF-7 FFAR3 cells after propionate 
treatment demonstrated a significant reduction in cAMP concentration, 
suggesting receptor activation (Figure 23A). This effect was also demonstrated 
in overexpressed FFAR3 MDA-MB-231, but to a lesser extent (Figure 23 B). 
For both MCF7 and MDA-MB-231 cells overexpressing FFAR2, the cAMP 
levels in propionate-treated cells remained similar to those of vehicle-treated 
ones.  
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Figure 23: FFAR3 inhibits the cAMP production representing GaI/0 coupling 
Propionate-induced FFAR3 activation decreases cAMP levels when stimulated 
with 5μM FSK in (A) MCF-7 and 25μM FSK in (B) MDA-MB-231. However, 
this effect is not observed in FFAR2 cells. The results shown are representative 
of 3 independent experiments with error bars representing the mean ±SD, * p 
<0.05, ** p <0.01, *** p <0.001 N=3.  
 
3.2 Investigating possible roles of FFAR2 and FFAR3 in Epithelial 
Mesenchymal Transition (EMT) 
 
EMT is a process where the epithelial cells undergo multiple molecular changes 
to switch to mesenchymal state. EMT is an essential step for cancer progression 
(Zeisberg and Neilson 2009). FFAR2 and FFAR3 in cancer studies has shown 
potential anti-tumorigenic effects, however the function of the receptors in 
EMT- and metastasis-related activities is not understood. Therefore, this section 






3.2.1 An upregulation of E cadherin in FFAR2 over-expressing MDA-
MB-231  
 
Initially, a qPCR screen for a few crucial markers of EMT was performed in 
MDA-MB-231 over-expression cells without stimulating the receptors. There 
was a significant increase in CDH1 and decrease in VIM genes in FFAR2 group, 
the effects were not observed in FFAR3 groups as shown in Figure 24 A. the 
FFAR2-mediated increase in CDH1 was exacerbated by treatment with 
propionate (Figure 24 B).  
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Figure 24: E Cadherin gene expression is upregulated by FFAR2 over-
expression and stimulation                                             
A qPCR analysis was performed to evaluate the EMT markers in MDA-MB-
231 FFAR2 and FFAR3 over-expression cells (A) Activation of CDH1 (E 
Cadherin) (B) CDH1 expression upon 1mM propionate stimulation in MDA-
MB-231 FFAR2 and FFAR3 overexpressed cells. Cells were serum starved for 
four hours, followed by treatment with propionate or vehicle for 4 hours. The 
results shown are representative of 3 independent experiments with error bars 
representing the mean ±SD, * p <0.05, ** p <0.01, *** p <0.001 N=3. 
3.2.2 A significant increase in E cadherin activation in FFAR2 over-
expressed MDA-MB-231 
 
MDA-MB-231 cells showed a significant upregulation of E-Cadherin protein 
level in vehicle-treated FFAR2 cells as compared to vehicle-treated pcDNA3.1 
vector control. A further increase in propionate-induced E-Cadherin level was 
observed in MDA-MB-231 FFAR2 cells (Figure 25 A & B). In MCF-7 FFAR2 
cells, there was a slight increase in E-Cadherin activation upon propionate 
application, however it was not observed to be significant compared to vector 
control propionate treated (Figure 25 C & D). E-Cadherin in both MCF-7 and 
MDA-MB-231 remained unchanged.  
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Figure 25: MDA-MB-231 FFAR2 significantly augments E cadherin protein 
levels                                                           
(A) A western blot analysis was performed to evaluate the E Cadherin changes 
in MDA-MB-231 FFAR2 and FFAR3 over-expression cells. (B) is the 
quantitation of A. (C) E Cadherin changes in MCF-7 FFAR2 and FFAR3 over-
expression cells. (E) is the quantitation of C. Cells were serum starved for four 
hours, followed by treatment, as described in Section 2.1.2, for another four 
hours. Β-Actin was used a loading control. The values are normalised to vehicle 
treated vector control group. * p <0.05, *** p <0.001. The results shown are 
representative of 3 independent experiments with error bars representing the 
mean ±SD, N=3.  
3.2.3 A significant decrease in Vimentin gene expression in FFAR2 over-
expressing MDA-MB-231 
 
Upon observing a significant reduction in vimentin expression in FFAR2 MDA-
MB-231 cells (Figure 24 A), the cells were subjected to propionate treatment 
and a qPCR was performed to analyze the vimentin expression. A significant 
decrease in VIM mRNA levels was observed in FFAR2 group. A similar effect 
was observed in FFAR3 group, however propionate- mediated effect is not 
detected. Figure 26 B, ICC labelling for vimentin protein shows a slight 
reduction in labelling in FFAR2 condition, however the effect was not found to 
be significant (Figure 26 B & C).  
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Figure 26: MDA-MB-231 FFAR2 upon propionate stimulation lowers 
vimentin  
A) qPCR analysis was conducted to study the vimentin (VIM) gene expression 
in FFAR2 & FFAR3 expressing MDA-MB-231 cells, upon propionate or 
vehicle treatment for 4 hours and C) An immunocytochemistry labelling was 
done for vimentin protein at 4hrs of vehicle or propionate treated cells. The 
merged images show the DAPI nuclei staining. D) Quantification of C. The 
values are normalised to vehicle treated vector control group. * p <0.05, *** p 
<0.001. The results shown are representative of 3 independent experiments with 
error bars representing the mean ±SD, N=3.  
 
3.2.4 A reduced cell invasion observed in MDA-MB-231 overexpressing 
FFAR2 and FFAR3 
 
E Cadherin expression is a characteristic feature of epithelial phenotype. 
Phenotype governs the functional aspects of cancer cells like invasion and 
migration. E cadherin is predominantly known to regulate cell-cell adhesion, 
also there are studies indicating the loss of E-Cadherin leading to increased 
invasion in many metastatic tumors including breast cancer (Wendt, Taylor et 
al. 2011). Hence, we looked at the invasion property of the MDA-MB-231 
FFAR2 and FFAR3 over-expression cells using a matrigel invasion assay as 
shown in Figure 27 A & B. The figure shows significantly less invasion in 
MDA-MB-231 FFAR2 and FFAR3 cells treated with propionate when 
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compared to vector control 
                 
                 
Figure 27: MDA-MB-231 FFAR2 and FFAR3 significantly abrogates 
invasion of the cells 
A) Representative images of matrigel invasion chambers demonstrate the effect 
of the vehicle and propionate treated for 4 hours on the invasion potential of 
FFAR2 and FFAR3 overexpressing and vector control MDA-MB-231. B) 
Quantitation of cell invasion is performed by counting the number of cells 
invaded using ImageJ software. The scale size is 50µm. The results shown are 
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representative of 3 independent experiments with error bars representing the 
mean ±SD, * p <0.05, ** p <0.01, *** p <0.001 N=3.  
 
3.2.5. FFAR2 and FFAR3 reduces number of cells with stress fibres 
 
EMT- driven notable changes in actin-cytoskeletal changes is another feature of 
cancer progression (Haynes, Srivastava et al. 2011). Thereby, to understand the 
cytoskeletal changes with respect to modified EMT markers, we performed a 
phallodin stain as shown here in Figure 28 A & B. FFAR2 and FFAR3 possess 
significantly fewer cells with observable stress bundles in ligand treated group 
in comparison to vector control group. 














           
Figure 28: MDA-MB-231 FFAR2 reduces the stress fibres 
A) Representative images of phalloidin staining demonstrates the cells with 
stress fibres. The cells were treated with either vehicle or 1mM propionate for 
4 hours. The merged images show the nuclei staining with DAPI for their 
respective fields B) Quantitation of the images was done by counting the 
number of cells possessing stress fibers, 5 fields were randomly selected. The 
scale size is 10µM. The results shown are representative of 3 independent 
experiments with error bars representing the mean ±SD, * p <0.05, ** p <0.01, 
*** p <0.001N=3.  
 
3.2.6. FFAR2 and FFAR3 enhance the drug sensitivity in MCF-7 and 
MDA-MB-231 cells 
 
This section investigated whether overexpressed FFAR2 and FFAR3 
specifically confers chemotherapy drug resistance, MTT assay was performed 
on members of three different classes of chemotherapy drugs: doxorubicin, 
cisplatin and paclitaxel. The cell lines were treated with 1mM propionate in the 
assay. Increasing drug concentration caused a predicted dose-dependent 
decrease in cell viability (Figure 29). MCF-7 FFAR2 and FFAR3 over-
expression cells exhibited a significant sensitization to cisplatin and paclitaxel 
relative to vector control (Figure 29 A to C). However, MDA-MB-231 cells did 
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not show the same effect for cisplatin and paclitaxel, instead, there was a 
significant change for doxorubicin observed in FFAR2 group in comparison to 
vector control (Figure 29 D to F). This indicated that FFAR2 and FFAR3 
overexpression increases cell sensitivity or reduces drug resistance to certain 
chemotherapy drugs.    
 
Figure 29: FFAR2 and FFAR3 expression enhances the drug sensitivity in 
breast cancer cells          
MTT assay was performed for testing the drug resistance to three different 
chemotherapeutic drugs in over-expression cells (A-C) in MCF-7 and (D-F) in 
MDA-MB-23. The cells were serum starved for 4 hours followed by treatment 
with 1mM propionate and the drugs for 72 hours before the MTT assay was 
performed. Data representative of 3 independent experiments, error bars 
















3.3. Investigating MAPK pathway in FFAR2 and FFAR3 over-expression 
system 
 
Proliferation is an important hallmark of cancer. There are various pathways 
through which cancer cells enable unlimited cell growth signals, among the 
proliferative pathways, ERK/MAPK is the most common pathway that is 
dysregulated in many cancer types leading to uncontrollable cell growth 
(Downward 2003) (Hynes and Lane 2005). In addition, in the recent years, 
Hippo-YAP pathway has started to gain attention in cancer studies. Hippo-YAP 
pathway is known for its role in controlling the organ size. An abnormality in 
the functioning of these signaling cascade leads to increased proliferation of 
cells. This section focuses on the studying the role of FFAR2 and FFAR3 in 
regulating ERK/MAPK and Hippo/YAP proliferative mechanisms. 
3.3.1. FFAR3 over-expression inhibits p44/42 ERK and P38MAPK 
activation  
 
Here we intend to study the possible role of FFAR2 and FFAR3 in modulating 
the ERK/p38MAPK pathways. Western blot was performed to investigate 
receptor-mediated effect in ERK. As Figure 30 A & B shows, FFAR2-mediated 
ERK effect is not observed in MDA-MB-231, yet FFAR3 over-expression 
exhibited a significant decrease in 44/42 pERK, though propionate mediated 
effect was not observed. In MCF-7 cells both FFAR2 and FFAR3 did not 
change the ERK activation levels (Figure 30 E). Another essential marker of the 
MAPK pathway, p38MAPK was also tested, Figure 30 C & D exhibits the 
similar trend as ERK. FFAR3 reduces the pP38MAPK levels but propionate-
mediated effect was absent. P38 levels are unchanged in FFAR2 
overexpressingcells. 
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Figure 30: FFAR3 reduces p44/42 ERK and P38MAPK activation                    
A) A western blot shows the p44/42-ERK phosphorylation in MDA-MB-231 
FFAR2 & FFAR3 over-expressing cells treated with 1mM propionate and 
vehicle for 5mins after 4hours serum starvation. B) Quantification of A, ratio of 
pERK to tERK is shown. C) A western blot analysis for P38-MAPK 
phosphorylation in FFAR2 & FFAR3 over-expressing MDA-MB-231 cells 
treated with 1mM propionate and vehicle for 5mins after 4hours serum 
starvation. D) Quantification of C, ratio of pP38MAPK to tP38MAPK is shown. 
E) western blot analysis of pERK and ERK in MCF-7 FFAR2 and FFAR3 
(N=2). Β Actin is used as loading control. * p <0.05. The results shown are 
representative of 3 independent experiments with error bars representing the 











3.3.2. FFAR2 over-expression inactivates YAP by phosphorylating at 
ser127 site in MDA-MB-231 cells 
 
Hippo-YAP pathway participate in uncontrolled proliferation in cancer 
environment. After studying the MAPK pathway markers, we went on to 
examine the involvement of FFAR2 and FFAR3 in regulating cell growth 
involving Hippo-YAP pathway. To begin with, we looked at the most essential 
marker for this pathway, YES Associated Protein (YAP). The phosphorylation 
at Ser127 site reduces the activity of YAP, thus, reducing cell growth. Figure 
31 A & B indicates that MDA-MB-231 FFAR2 cells upon propionate 
stimulation enhances the phosphorylation of YAP in contrast to vector control. 
On the other hand, FFAR3 over-expression demonstrates an increased pYAP, 
which does not further increase upon ligand stimulation. MCF-7 over-
expression cells showed insignificant slight increase in phosphorylation (Figure 
31 C) 
 










                       
 
       
Figure 31: FFAR2 significantly elevates the activation of YAP 
phosphorylation 
A) A western blot shows the YAP phosphorylation in FFAR2 & FFAR3 over-
expressing MDA-MB-231 cells treated with 1mM propionate and vehicle for 
4hours after 4hours serum starvation. B) Quantification of A, ratio of pYAP to 
YAP is shown. C) Western blot analysis of YAP phosphorylation in MCF-7 
over-expression lines, cells treated with 1mM propionate, 1uM LPA (as positive 
control) and vehicle for 4hours after 4hours serum starvation (N=2). Β Actin is 
used as loading control. The results shown are representative of 3 independent 
experiments with error bars representing the mean ±SD, * p <0.05, ** p <0.01, 
*** p <0.001 N=3.  
 
 




LATS1/2 (Large Tumor Suppressor1/2)  are the two critical proteins responsible 










cytosol (Harvey, Zhang et al. 2013). When Hippo pathway is activated MST1/2 
activates LATS1/2, thereby, shutting off the YAP activity (Hansen, Moroishi et 
al. 2015). Moreover, LATS1/2 is shown to be directly regulated by GPCRs  
(Yu, Zhao et al. 2012 
)Thus, we performed protein analysis for LATS1/2, whereby, we identify that 
LATS1 and LATS2 was significantly upregulated in FFAR2 upon propionate 
administration (Figure 32 A & B).  
 
              
 















                
                
Figure 32: FFAR2 stimulation enhances the activation of LATS1 &LATS2 
protein. 
Western blot analysis shows the LATS1 (A) and LATS2 (B) activation in both 
FFAR2 & FFAR3 MDA-MB-231cells. The cells were serum starved for 4 hours 
followed by 4 hours of 1mM propionate treatment. Quantification of LATS1 
(C) and LATS2 (D) ratio of LATS1/2/B actin is shown. The results shown are 
representative of 3 independent experiments with error bars representing the 
















3.3.4. FFAR2 and FFAR3 expression is downregulated in various types of 
breast carcinoma tissues  
 
The Curtis breast dataset obtained from Oncomine was analyzed for the 
expression of FFAR2 and FFAR3 mRNA in 1992 breast carcinoma and 144 
paired normal breast samples. Whiskers plot represent the min to max values 
and one-way ANOVA was performed to calculate significance. FFAR2 is 
shown to be significantly reduced in invasive ductal carcinoma breast tissues 
(Figure 33 A) and FFAR3 expression is observed to be greatly reduced in all 
types of breast carcinoma with p value 0.0001 (Figure 33 B). Particularly in 
breast carcinoma tissues that possess triple negatives status both FFAR2 and 
FFAR3 showed a significant reduction of mRNA levels (Figure 33 C &D).  
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Figure 33: FFAR2 and FFAR3 expression is reduced in Curtis breast cancer 
tissues 
FFAR2 (A) and FFAR3 (B) gene expression in a panel of various breast 
carcinoma tissues data extracted from the Curtis breast dataset. (C) and (D) 
represent the expression pattern of FFAR2 and FFAR3 respectively in triple 
negative breast cancer tissues in comparison to normal breast tissues. One way 
ANOVA was performed for A & B. Student T Test was performed C & D. p 














Discussion (Part I) 
The major objective of this portion of the project is to study the roles of FFAR2 
and FFAR3 in regulating the breast cancer condition. We started with 
identifying the appropriate cell line for our study. A qPCR screen was 
performed to identify breast cancer cells with low expression levels of FFAR2 
and FFAR3 for over-expression studies. Our qPCR screen determined a lower 
expression of FFAR2 and FFAR3 (Figure 20) in MDA-MB-231 and MCF7 
cells. These cell lines are particularly amenable to our studies since they 
demonstrate contrasting phenotypes. MCF-7 is more of an epithelial-like cell 
line which is positive for estrogen receptor and negative for HER2 status, 
classified under Luminal A subdivision. Whereas, MDA-MB-231 is more of a 
mesenchymal- like cell line, which is negative for estrogen, progesterone and 
HER2 receptors in other words, triple negative (Subik, Lee et al. 2010). Upon 
testing the functionality of the receptor construct (Figure 21 A), the receptors 
were stably over-expressed in MCF-7 and MDA-MB-231 cells. The engineered 
over-expression cells were validated by immunocytochemistry for V5 labelling 
(Figure 21 B), Similarly, mRNA expression levels of the FFAR2 and 3 genes 
were tested which signifies the successful over-expression of the receptors 
(Figure 21 C & D). It is substantially supported that FFAR2 and FFAR3 is 
activated by short chain fatty acids such as, propionate, butyrate and acetate. In 
our next aim of identifying a suitable ligand for both the receptors, basing upon 
the available studies, propionate is shown to activate both the SCFA receptors 
with equal potency (Brown, Goldsworthy et al. 2003). Propionate was selected 
as ligand for FFAR2 and FFAR3 and it was validated using TGFα shedding 
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(Inoue, Ishiguro et al. 2012). Figure 22 A & B, demonstrate that propionate 
activates FFAR2 and FFAR3 by displaying a dose- dependent increase in the 
AP- TGFα shedding. Functioning mechanism of a GPCR is determined by the 
G-protein it is coupled to (Fredriksson, Lagerström et al. 2003). From the 
previous evidence, FFAR3 is strongly supported for its coupling to Gai/o, 
whereas FFAR2 is predominantly shown to associate to Gaq/11 though a few 
reports have studied its coupling to Gai/o (Le Poul, Loison et al. 2003). We 
further moved on to test if FFAR2 and FFAR3 are responsive to cAMP assay 
that determines the Gai/o coupling. It is seen that FFAR3 presented a significant 
drop in cAMP concentration, by which it means, Gai/o induction upon ligand 
treatment stimulates adenylyl cyclase which subsequently reduces the 
intracellular cAMP levels, indicating that FFAR3 is associated with Gai/o, 
whereas FFAR2 did not reduce the cAMP levels, this indicates the absence of 
Gai/o coupling of FFAR2 (Figure 23 A & B).    
90% of cancer-associated deaths occur due to the ability of cancer cells to 
metastasize from the primary site to secondary sites through lymphatic or blood 
vessels (Gupta and Massague 2006). The invasion-metastasis pathway involves 
multiple processes, it begins with the loss of adhesion ability of the cancer cells, 
making them free to move, leading to migration and invasion into secondary 
sites (Massague and Obenauf 2016).  EMT is one of the important initial steps 
in metastatic cascade, where the cells undergo progressive remodeling into 
mesenchymal cells (Scully, Bay et al. 2012). The majority of pathways that 
initiate EMT converges to activate EMT-related transcription factors, such as 
SNAIl, SLUG, ZEB and TWIST, which further regulates the EMT regulated 
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proteins (Peinado, Olmeda et al. 2007). The differential expression of CDH1, 
VIM, SNAI1 and SNAI2 are shown to lead to EMT (Taylor, Parvani et al. 2010). 
Destabilization of cell-cell contact is an essential feature in intermediate state 
of EMT. Intercellular adhesion at the junction site is mediated by the major 
transmembrane protein, E-cadherin (cadherin 1 [CDH1]), which is essentially a 
traditional marker for the EMT process (Kotiyal and Bhattacharya 2016). Thus, 
we intended to examine the EMT marker expression in MDA-MB-231 FFAR2 
& MDA-MB-231 FFAR3 cells. We screened MDA-MB-231 FFAR2 and 
FFAR3 cells for CDH1, SNAII, SNAI2 and VIM. We identified that CDH1 (gene 
for E Cadherin) (Figure 24 A &B) and protein level (Figure 25 A &B) was 
upregulated only in FFAR2 over-expressing MDA-MB-231, not in FFAR3 
over-expressing cells. Surprisingly, CDH1 was significantly increased in the 
FFAR2 expressing cells, whereas the other transcriptional marker levels remain 
unchanged in the cell line. CDH1 is known to be regulated by other means. One 
such regulator of E-cadherin is miR-9, a MYC/MCYN activated micro-RNA, 
which is identified as s pro-metastatic miRNA and negative regulator of the 
epithelial marker and metastatic inhibitor, E Cadherin. Studies have shown that 
MYC/MYCN activates miR-9. This miR-9 directly binds to the 3’-UTR region 
of the CDH1 to downregulate E cadherin. Moreover, ß-Catenin which is 
attached to the cytoplasmic tail of the E-cadherin liberates and translocate to 
nucleus thus activating pro-metastatic factors, in this case pro-angiogenic factor 
VEGFA. In addition, the miR-9 expression is significantly upregulated in 
clinical breast cancers, moreover, metastatic cancer cells express even higher 
levels of miR-9 than non-metastatic cancers (Ma, Young et al. 2010) (Liu, Zhu 
et al. 2013). Similarly, VIM (gene for vimentin) expression was downregulated 
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in both FFAR2 & FFAR3 (Figure 26 A), however, ICC for vimentin showed 
only a slight decrease without a significant p value (Figure 26 C). In MCF-7 
FFAR2, E Cadherin protein level, though displayed a slight increase, the change 
was not significant (Figure25 C & D), therefore the further EMT-related studies 
were carried out in MDA-MB-231 cells that demonstrated a significant change 
in EMT-related markers. we ascribed the absence of significant E-cadherin 
upregulation in MCF-7 cells to its epithelial nature, where endogenous high 
levels of E-cadherin are presented further masking the effect upon receptor over 
expression and activation (Batlle, Sancho et al. 2000).  
Local invasion of the cancer cells from their primary site to secondary organs 
facilitated by intravasation into the lymphatic and blood vessels is an essential 
step in the process called metastasis (Hunter, Crawford et al. 2008). For the 
same reason, the cancer cells lose their cell-cell adhesion to be able move and 
undergo invasion, for which, they primarily disrupt the cell-cell adhesion 
molecules and the association with extracellular matrix proteins (Li and Feng 
2011). E cadherin is principally known to regulate cell- cell adhesion, 
suggesting that loss of E cadherin can lead to an increase in invasion in various 
cancer types including breast cancer, as shown from various studies (Wendt, 
Taylor et al. 2011). Based on the previous literature findings and upon observing 
upregulation in E-cadherin (Figure 25 A), we decided to test the invasiveness 
of MDA-MB-231 FFAR2 & 3 cells. A matrigel invasion assay was performed, 
where we identified less number of cells invaded in FFAR2 and FFAR3 
condition in comparison to vector control (Figure 27 A & B). Our results 
suggest that FFAR2 and FFAR3 activation by propionate reduces the invasion 
of MDA-MB-231 cells contrasted to the vector group.  
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For a successful metastatic invasion to occur, besides losing cell-cell contact, 
cells undergo morphological changes that enable its progress towards the far 
away organs. Actin filament plays an important role in facilitating this event. In 
epithelial cells the actin filaments are more organized as thin bundles, whereas 
in mesenchymal cells, transdifferentiated and thick bundles of stress fibres are 
observed (Lamouille, Xu et al. 2014). Various studies have shown notable 
changes in EMT-driven actin cytoskeletal changes (Haynes, Srivastava et al. 
2011). Cell movement in EMT is mediated by reorganization of actin 
cytoskeletal bundles and formation of filopodia. These actin rich stress fibres 
and filopodia degenerates the extracellular matrix (ECM) and stimulates 
invasion (Lamouille, Xu et al. 2014). Therefore, next we aimed at studying 
cytoskeletal alterations that is associated to epithelial phenotype. Phalloidin 
labelling for the actin bundles reveal fewer percentage of cells with stress fibres 
in FFAR2 and FFAR3 propionate-treated condition unlike the vector control. 
Further supporting our findings that FFAR2 and FFAR3 over-expressing cells 
are restricted from undergoing EMT (Figure 28 A & B).  
Chemotherapy is one of the leading modes of cancer therapy. Cancer cells can 
exhibit various mechanism, such as, inhibition of cell death, alternative 
signaling mechanism, DNA damage repair, mutations in drug targets and high 
drug efflux to escape the drug treatment by becoming insensitive to 
chemotherapy (Holohan, Van Schaeybroeck et al. 2013). The EMT process is 
well documented for its association to resistance to chemotherapeutic drugs 
(Singh and Settleman 2010). EMT is also found to be linked to cancer stem cells 
(CSCs), by generating self-renewing cells, which is contributed to the 
tumorigenesis and multi-drug resistance (Gunasinghe, Wells et al. 2012). 
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Furthermore, EMT markers have been observed in tumor biopsies from patients 
who acquired drug resistance, indicating that EMT-linked cancer drug 
resistance occurs in the clinical settings (Holohan, Van Schaeybroeck et al. 
2013). Hence we tested our over-expression cells for their sensitivity towards 
three chemo drugs: 1) doxorubicin- it is an anthracycline involved in 
intercalation into DNA, inhibiting topoisomerase II, thus preventing DNA and 
RNA synthesis (Chaires 1990), 2) cisplatin- a platinum-based chemotherapy 
drug and is also an alkylating agent, 3) paclitaxel- a cytoskeletal drug that targets 
tubulin (Bharadwaj and Yu 2004). In general, our data suggest that FFAR2 
over-expression results in increased sensitivity of cells to doxorubicin, cisplatin, 
and paclitaxel treatment, particularly the effect observed in doxorubicin and 
paclitaxel treated group showed a strong significant effect as shown in Figure 
29 B, C & D. On the other hand, FFAR3 improved the sensitivity to cisplatin 
and paclitaxel in MCF-7 cells (Figure 29 B & C). Since upregulation of EMT 
markers is found to be associated with development of drug resistance in cancer 
cells, FFAR2 and 3 overexpression may be inducing the reverse of EMT, which 
is MET, leading to reversed drug resistance and improved sensitivity to 
chemotherapy drugs. For example, a study has specifically shown decreased E-
cadherin is associated with drug resistance in pancreatic cancer cells 
(Arumugam, Ramachandran et al. 2009) and ZEB1, an EMT activator, is 
reported to be strongly linked to therapy-resistant phenotype  (Zhang, Sun et al. 
2015). However, when ZEB1 is depleted in the resistant pancreatic cancer cell 
line, Panc1, it leads to re-differentiation and re-sensitization to gemcitabine, a 
chemotherapy drug. Thus, with these supporting findings and our results, 
FFAR2 and FFAR3 may play a role in EMT inhibition, thus sensitizing the cells 
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towards chemotherapeutic drugs, subsequently preventing metastasis.  
Additionally, we focused into an important hallmark of all cancers i.e., 
accelerated cellular growth driven by sustained proliferative signaling. Cancer 
cells are known to exhibit limitless growth leading to macroscopic tumor mass 
(Zvereva, Shcherbakova et al. 2010). Various proliferative pathways are studied 
in cancer conditions, amongst all, ERK proliferative pathway is extensively 
studied as this is dysregulated in one third of cancers (Dhillon, Hagan et al. 
2007). Upon mitogen stimulation, ERK (ERK1 and ERK2) becomes 
phosphorylated and activated. An activated ERK is then translocated into the 
nucleus where it regulates several transcription factors such as Elk1 that 
promote cellular proliferation (Cruzalegui, Cano et al. 1999). Literature has 
shown FFAR2 and FFAR3-mediated ERK activation upon propionate and 
acetate treatment in CHO-K1 cells (Le Poul, Loison et al. 2003, Seljeset and 
Siehler 2012), resulting in cancer proliferation (Kim, Kim et al. 2012), yet 
FFAR2 is reported for attenuating ERK activation in human monocytes (Ang, 
Er et al. 2016) and T. Yonezawa et al. (2007) accounted absence of ERK 
phosphorylation upon FFAR2 activation in MCF-7 cells rather p38MAPK was 
selectively upregulated (Yonezawa, Kobayashi et al. 2007) however  only a 
weak association of FFAR2 & FFAR3 with p38MAPK was observed in a study 
by Le poul et al (Le Poul, Loison et al. 2003, Seljeset and Siehler 2012). From 
the above evidence, it is understood that role of FFAR2 & FFAR3 in regulating 
MAPK pathway still remains unanswered. Consequently, we studied the ERK 
activation in FFAR2 & FFAR3 expressing MDA-MB-231 and MCF-7 cells. As 
seen in Figure 30 A, in MDA-MB-231 cells, there is no significant difference 
in pERK and ERK levels in FFAR2, however FFAR3 over-expression displays 
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a significant decrease in pERK. Further, relative ratio of pERK/ERK confirms 
the observation (Figure 30 B), however the similar trend of decreased pERK 
upon FFAR3 over-expression was absent in MCF-7cells (Figure 30E). This 
implies that ERK activation is not mediated by FFAR2 in both MCF-7 and 
MDA-MB-231 cells, corresponding to the report by Yonezawa et al (Yonezawa, 
Kobayashi et al. 2007), however, FFAR3 mediated ERK reduction in MDA-
MB-231 and not in MCF-7 cells is presumably a cell-type specific action. A 
western blot analysis was carried out to determine the activation of p38MAPK, 
MDA-MB-231 FFAR3 over-expression cells reduce the p38MAPK activation, 
yet propionate-mediated effect was unseen (Figure 30 C & D), conversely, 
FFAR2 exhibited no change in p38MAPK. To summarize our ERK/ p38MAPK 
findings, FFAR2 is not involved in regulating ERK/ p38MAPK, it is possible 
that FFAR3 is involved in downregulating the ERK/p38MAPK pathway though 
the effect is cell line specific, in other words, a possible role of FFAR3 in 
inhibiting cell invasion and decrease in E-cadherin unlike FFAR2 is mediated 
by inhibiting MAPK pathway can be expected. The inconsistency in FFAR2- & 
FFAR3- mediated regulation of ERK/P38MAPK in previous studies and our 
data is perhaps as a result of cell-type dependent response.  
Recently, the Hippo-YAP pathway has demonstrated to be an essential mediator 
in maintaining the organ size and cell growth during the early developmental 
stages (Zhao, Tumaneng et al. 2011). Upregulation of YAP activity has been 
discovered in multiple human cancers such as liver, skin and colon cancer, 
however the mechanism underlying the effect remains unclear. One of the key 
downstream effector protein of the Hippo pathway is the Yes Associated Protein 
(YAP) protein, in dephosphorylated state it actively translocates to the nucleus 
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and enable transcription of target genes involved in cell proliferation. YAP is 
currently regarded as an oncogene that is able to promote cell growth (Johnson 
and Halder 2014). Activation of LATS1/2 (Large Tumor Suppressor) kinases, 
upstream regulator of YAP (and inactivation of YAP/TAZ) represents the major 
functional output of the Hippo pathway. In addition, a study in 2012, established 
an association between GPCRs and YAP signaling, YAP and TAZ are 
transcription coactivators, and their activation/inhibition may therefore play an 
important role in GPCR-mediated gene regulation. GPCRs coupled to Gαq, 
Gα12/13 and Gαi/o activates YAP by inhibiting the activation of LATS1/2 thus 
preventing the phosphorylation of YAP, while, GPCRs coupled to Gαs inhibits 
YAP activity by activating LATS1/2. They have also shown that FFAR1 that 
couples to both Gαq and Gαi/o to upregulate YAP signaling (Yu, Zhao et al. 
2012 
)We investigated the possible involvement of FFAR2 and FFAR3 in Hippo-
YAP proliferative pathway. LPA was selected as a positive control, as the study 
by has shown that it acts through LPAR1 to significantly enhance the YAP 
activity by reducing its phosphorylation (Yu, Zhao et al. 2012) 
Results show that FFAR2 upon activation by propionate increases the YAP 
phosphorylation, which otherwise means reduced YAP activity. However, this 
effect was observed in MDA-MB-231 (Figure 31 A) and not in MCF-7 cells 
(Figure 31 C), which denotes that the FFAR2 reduction in YAP activity is 
specific to MDA-MB-231 cells. FFAR3 did not have any propionate-mediated 
change in both MDA-MB-231 (Figure 31 A) and MCF-7 (figure 31 C). Upon 
observing the YAP regulation, we went ahead to check the levels of its 
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immediate upstream effector LATS1/2 in MDA-MB-231 cells, as it is known 
to be directly involved in phosphorylating YAP and GPCRs on the other hand, 
directly influences LATS1/2 activation (Yu, Zhao et al. 2012 
)Figure panel 32 demonstrates that FFAR2 is involved in increasing the LATS1 
and LATS2 protein levels (Figure 32 A & B) and FFAR3 increases LATS1 
protein level (Figure 32 A), this result is in line with our observation with 
respect to YAP protein levels. Taken together, we identify that FFAR2 is 
involved in regulating the YAP phosphorylation by activating LATS1 and 
LATS2, thus suggesting that FFAR2 receptor activation function towards anti-
proliferation. While, FFAR3 over-expression demonstrates decreased ERK and 
p38MAPK, suggesting its anti-proliferative role taking place through the ERK 
pathway, however, propionate-mediated effect was not predominantly 
observed, this is could be due to constitutive activation of GPCRs as already 
elaborated in chapter 1 (section 1.1.4). GPCRs are shown to be constitutively 
activated by repetitive application of excessive ligand, according to a few 
reports (Alewijnse, Timmerman et al. 2000). Besides, an interesting implication 
of ligand-independent effects observed in FFAR3 is probably due to an 
overlapping signaling mechanism. GPCRs are well documented for receptor 
tyrosine kinase mediated transactivation of G proteins, same way GPCRs are 
also shown to trans activate EGF and PDGF receptors (Pyne, Waters et al. 
2003), in addition such non classical activation of G-proteins are shown to be 
regulating MAPK pathway (Pierce, Premont et al. 2002). Also non canonical 
factors regulating GPCR activation includes extrinsic perturbations like, 
agonist, cholesterol, lipids and other growth factors, while intrinsic 
perturbations include natural or experimental gain or loss of function or 
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chemical modifications of residues.  
Moving forward, we intended to understand the clinical implications of our 
findings. We started investigating the expression of FFAR2 and FFAR3 in 
breast carcinomas. For the same reason, we analyzed the Curtis breast dataset 
(Curtis, Shah et al. 2012) available on Oncomine database, which has a gene 
expression profile of (1992) breast carcinoma samples and (144) paired normal 
breast tissue. Our analysis reveals that FFAR2 expression is significantly 
reduced in invasive ductal carcinoma types among the panel (Figure 33 A). 
Even a greater significant pattern was observed with the expression levels of 
FFAR3, where almost all the breast carcinoma types studied showed a 
significant drop in FFAR3 expression (Figure 33 B). In general, most of our 
significant results were specific to MDA-MB-231 cells, which is triple negative 
status and more mesenchymal- like cell line, thereby we specifically analyzed 
the datasets for triple negative breast tissues in comparison to normal breast 
tissues, as expected, FFAR2 and FFAR3 expression was greatly reduced 
(p<0.0001) (Figure 33 C & D). This result signifies that FFAR2 and FFAR3 
expression is significantly lost in various types of breast carcinoma. In line with 
our results, a study has identified reduced FFAR2 expression in colorectal 
adenocarcionoma tissues. Upon restoration of FFAR2 in the colon cancer cells, 
an increased apoptosis and reduced proliferation was observed (Tang, Chen et 
al. 2011). This further provides an evidence that FFAR2 and FFAR3 functions 
as tumor-suppressors in breast cancer cells.  
In conclusion, we investigated the role of FFAR2 and FFAR3 in breast cancer 
cells (Figure 34). For the first time, we identify that FFAR2 and FFAR3 
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mediates anti-tumorigenic effect. FFAR2 modulates the EMT-related canonical 
markers (E cadherin & Vimentin) and its associated functional changes like 
reduced invasion is observed. In addition, FFAR2 is attributed to modulate the 
proliferative function of breast cancer cells through the critical Hippo-YAP 
pathway mediators, LATS1/2 and YAP. Similarly, FFAR3 over-expression is 
shown to be inhibiting the two proliferative pathways, ERK activation and 
improved phosphorylation of YAP at ser-127, two pathways essential for the 
progressive proliferation of cancer cells. Although, with FFAR3, EMT related 
markers was not altered as significantly as FFAR2, the invasion capability of 
cancer cells has revealed that FFAR3 stimulation reduces the invasion. 
Moreover, Curtis datasets, exhibits reduced expression of FFAR2 and FFAR3 
in breast carcinomas, specifically, in triple negative breast cancer tissues. 























































































































































































































































































RESULTS & DISCUSSION  
(PARTII) 
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Chapter 4- Results (PART II) 
 
4.1 FFAR1 promotes tumorigenic pathways 
 
This part of the project focuses on the hypothesis that FFAR1 mediates the 
effects of LCFAs in activating tumor-promoting pathways. The involvement of 
FFAR1 in regulating ERK and the EMT-related regulators is studied.  
4.1.1 FFAR1 expression is upregulated in ductal breast carcinoma and 
invasive ductal and lobular breast carcinoma  
 
Expression level of FFAR1 was studied in breast carcinoma cells. The Curtis 
breast dataset available sourced from Oncomine was analyzed for the 
expression of FFAR1 mRNA in 1992 breast carcinoma and 144 paired normal 
breast samples. Whiskers plot represent the min to max values and one-way 
ANOVA was performed to calculate significance (Figure 35).  
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Figure 35: FFAR1 expression is increased in Ductal breast carcinoma and 
Invasive ductal and lobular Curtis breast carcinoma tissues 
FFAR1 gene expression in a panel of various breast carcinoma tissues data 
extracted from the Curtis breast dataset comparison to normal breast tissues. 
The significantly higher expression of the receptor FFAR1 was identified in 
ductal breast carcinoma and invasive ductal and lobular Curtis breast carcinoma 
tissues. Source of data: Oncomine database. * p <0.05, ** p <0.01, *** p <0.001 
 
4.1.2. MDA-MB-231 and MCF-7 expresses high and low levels of FFAR1 
respectively 
 
Upon observing the expression pattern in breast carcinoma tissues, FFAR1 
expression was characterized in a panel of breast cancer cells using qRT-PCR. 
Amongst the cell lines tested, two out of five had high levels of FFAR1 




Hence, MDA-MB-231 was chosen for preliminary studies on FFA stimulated 
FFAR1 functions. From the same assay, MCF-7 was detected to have low 
expression of FFAR1, hence it was chosen for the engineering of the FFAR1 
overexpression cell line.  
             
Figure 36: MCF-7 and MDA-MB-231 with low and high FFAR1 expression 
Qualitative PCR (qPCR) of a panel of breast cancer cells for their endogenous 





4.1.3 Engineer and validate the over-expression of FFAR1 in MCF-7 & 
MDA-MB-231 cells 
 
To test the functionality of the receptors, the pcDNA3.1/V5-His-TOPO 
containing FFAR1 in the multiple cloning site was transiently transfected into 
HEK293 cells for validation. Immunocytochemistry against V5 epitope tag 
showed membrane labelling in untreated cells, which internalized upon oleate 
treatment demonstrating ligand-mediated receptor activation (Figure 37 A).  
Generation of FFAR1 stable over-expression cells: Once the receptor 
functionality was confirmed, the vector containing FFAR1 was transfected into 
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MCF-7 cells, then cells were grown in Geneticin containing DMEM media to 
select the over-expression cells, because the vector contains neomycin resistant 
gene. Thus, FFAR1 was stably transfected into the desired cell lines.  
ICC for V5 labeling (Figure 37 B) and gene expression level using qPCR 
(Figure 37 C) was performed in these cell lines to validate the over-expression 
cells for further experiments. The reason for over-expressing FFAR1 in MDA-
MB-231 is discussed in following Discussion section (Part II).    
  














                   
Figure 37: Validation of FFAR1 construct and FFAR1-overexpressing 
MCF-7 
A) Immunocytochenistry V5- staining in HEK293 cells transiently transfected 
with FFAR1, untreated cells were directly fixed from full media. Oleate 
treatment group was serum starved for 4 hours and then stimulated with 
200uMoleate. The treated group shows the internalization of the receptor upon 
activation represented as puncta B) Immunocytochemistry V5 staining in stably 
transfected MCF-7. C) Cells grown in full media was collected and performed 
a qPCR analysis for the over-expression of FFAR1 in MCF-7. The results 
shown is representative image of 3 independent experiments.  
 
4.1.4 Long Chain Fatty acids- Oleate and Palmitate activates FFAR1 
 
Reports have shown that long chain fatty acids, particularly Oleate and 
palmitate has been shown to activate the receptor more efficiently (Itoh, 
Kawamata et al. 2003). In our study, we made use of TGF-a Shedding assay, a 
robust cell based assay which demonstrates the GPCR activation by means of 
% of AP-TGFa release which can be measured by the yellow colour developed 
by changing PNPP to PNP. The result implies that oleate and palmitate increases 




            
             
Figure 38: Oleate and Propionate activate FFAR1 
The TGFα-shedding assay was performed to evaluate the activation of FFAR1 
with the (A) oleate and (B) palmitate. The graph here shows the shedding % of 
AP-TGFɑ upon oleate and palmitate stimulation in HEK293 cells transfected 
with receptors and vector control construct. The results shown are representative 
of 3 independent experiments. N=3.  
 
4.2 Investigating the possible role of FFAR1 in proliferative and 
metastatic characteristics 
 
4.2.1 Oleate stimulates ERK activation in MDA-MB-231 
 
The initial studies to understand the role of FFAR1 in proliferative pathways 
were conducted in the cell line MDA-MB-231with high endogenous expression 
of FFAR1. Western blot was performed to examine and establish the dose and 
time dependent activation of the ERK levels. Activation of ERK was 




for 4hours, ERK was rapidly activated by oleate within 2.5 minutes, with 
activation peaking at 30 minutes (Fig. 39 A and B). ERK activation also 
increased as the dose increased, until it peaked at 200μM (Fig. 39 C and D).  
                    
                         
 


















                       
Figure 39: Oleate activates ERK in MDA-MB-231 in time- and dose- 
dependent manner 
A) ERK activation in MDA-MB-231 following 4 hours serum-starvation, then 
treatment for A) Indicated time points with 200 μM oleate. B) quantitation of 
A. C) Indicated oleate treatment at different concentrations for 5 minutes. 
Ethanol and BSA concentrations were standardized for all oleate concentrations 
D) Quantitation of C. The results shown are representative of 3 independent 
experiments. * p <0.05, ** p <0.01, *** p <0.001 N=3.  
 
4.2.2 Oleate application enhances the proliferation in MDA-MB-231 cells 
 
ERK activation has shown to be increased in the previous section, therefore, we 
went on to study phenotypic proliferation related to the increase in ERK levels. 
BrdU assay was performed to determine the rate of proliferation of cells upon 
FFAR1 activation. We find oleate treated MDA-MB-231 cells proliferate at a 









               
Figure 40: Oleate increases the proliferation rate in MDA-MB-231 cells 
(A) BrdU assay shows the rate of proliferation in MDA-MB-231 cells were 
serum starved for 4 hours and subjected to vehicle, 10% FBS, 200μM oleate 
treatment. Propidium iodide was used for total cell count (B) Quantification of 
the A. The results shown are representative of 3 independent experiments with 
error bars representing the mean ±SD, * p <0.05, ** p <0.01, *** p <0.001 N=3.  
 
4.2.3 Oleate administration to MDA-MB-231 cells increases migration 
 
Here we investigated oleate promoted migration of breast cancer cells in MDA-
MB-231 cells. A wound-healing assay was performed, the day scratch was made 
was considered as 0-time point, the closure of the wound was periodically 
checked at 24 and 48 hours upon oleate appliation. Results indicate that oleate 
treatment promoted migration of cells into the scratch-wound at a faster rate 
than the control treatment at 48hours, although slower than the rate induced by 
the positive control, EGF (Fig. 41 A and B). 
B
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Figure 41: Oleate induces wound healing in MDA-MB-231 cells  
(A) wound-healing assay determine the rate of wound closure in MDA-MB-231 
upon treatment with vehicle, 10% FBS and oleate at 0, 24, 48-hour time point 
and (B) Quantification of the A, area of scratch remaining at 48 hours is 
subtracted from 0 time and normalized to vehicle treated group. The results 
shown are representative of 3 independent experiments with error bars 


















4.3 FFAR1 mediated ERK and EMT-related markers in MCF-7FFAR1 
 
Literature evidence has shown that oleate, a potent ligand for FFAR1 is capable 
of inducing proliferation and metastasis- related activities like, migration and 
invasion in breast cancer cells. Therefore, in this section we aimed at studying 
the FFAR1- mediated effects of oleate in EMT- and ERK proliferation pathways 
in MCF-7 over-expressing FFAR1.   
4.3.1 Oleate- induced activation of FFAR1 does not demonstrate Gɑi 
signaling 
 
A cAMP assay was performed to determine whether Gαi/o activation was likely 
to be involved in the observed FFAR1-mediated responses. The assay was 
performed in MCF-7 vector and overexpression cells. 5µM forskolin was used. 
If FFAR1 activation activated Gαi/o, which in turn inhibits adenyl cyclase, 
cAMP levels would be expected to decrease. Activation of FFAR1 by FFAR1 
agonists oleate and GW9508 did not cause significant cAMP inhibition 
indicating an absence of observable Gαi/o signaling (Figure 42).  
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Figure 42: FFAR1 does not demonstrate Gαi/o signaling       
A) cAMP concentrations in MCF-7 vector and MCF-7 FFAR1 cells after 4-hour 
serum- starvation followed by 20 minutes treatment with control, 200 μM 
oleate, and 1 μM GW9508. The results shown are representative of 3 
independent experiments with error bars representing the mean ±SD, N=3. 
 
4.3.2 GW1100 is the antagonist for FFAR1- Validation 
 
GW1100 is an antagonist to FFAR1 (Briscoe, Peat et al. 2006). Here we intend 
to validate the functionality of the compound, before using it to study the 
receptor specific activation of ERK. The FFAR1 transfected HEK293 cells were 
subjected to oleate treatment, a positive control for receptor activation at 
different concentrations. Whereas, GW1100 group, the cells were pre-treated 
with varying concentrations of GW1100 for 30minutes followed by oleate 200 
μM fixed concentration (Figure 43).  
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Figure 43: GW1100 is a potent antagonist of the FFAR1 
TGF-ɑ shedding assay demonstrates the activation of FFAR1 on administering 
varying concentrations of Oleate, as a positive control and the effect is inhibited 
by adding the receptor antagonist GW1100 when pretreated for 30 minutes 
followed by oleate at fixed concentration 200uM. The results shown are 
representative of 3 independent experiments with error bars representing the 
mean ±SD, N=3.  
 
4.3.4 MCF-7 FFAR1 upregulates ERK activation on GW9508, agonist, 
which is inhibited by GW1100, antagonist of the FFAR1 
 
Demonstrating the ERK activation in MDA-MB-231 plausibly supports that 
FFAR1 is involved in mediating oleate mediated ERK upregulation. 
Consequently, the receptor specific action was identified to have similar effect 
in MCF-7 FFAR1 over-expression model, along with application of synthetic 
ligands. Here we show that ERK regulation is affected when oleate is applied 
to FFAR1 over-expressing MCF-7 cells (Figure 44 A), similarly, administration 
of GW9508, receptor agonist, shows a further enhanced activation of ERK when 
compared to oleate, natural ligand (Figure 44 A). Figure C shows that MCF-7 
FFAR1 cells pre-treated with receptor antagonist, GW1100 for 30 minutes 
followed by oleate application, blocked the ERK activation back to vector 
control level in the cells. 
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Figure 44: FFAR1 mediates ERK activation. Receptor agonist and antagonist 
enhances and blocks the activation respectively  
A) Western blot showing the ERK phosphorylation levels in MCF-7 FFAR1 
cells on oleate stimulation and further increase in 1 μM GW9508 treated group 
B) Quantitation of A. (C) ERK phosphorylation levels is inhibited by 
administering 10 μM GW1100, receptor antagonist (D) quantification of C. 
The data is a representation of 3 independent experiments with error bars 
representing the mean ±SD, * p <0.05, ** p <0.01, *** p <0.001 N=3.  
 
4.3.5 MCF-7 FFAR1 upregulates EMT related markers and alters the 
morphological features  
 
It is evident that long chain fatty acids, especially oleate and linoleate is 
involved in EMT-related processes, a study shows oleate can induce migration 
and invasion in breast cancer cells with an increase in MMP-9 (Soto-Guzman, 
Villegas-Comonfort et al. 2013) (Soto-Guzman, Navarro-Tito et al. 2010) , 
similarly linoleate is shown to increase EMT- relevant transcriptional factors 
like SNAII, SNAI2, TWIST in MCF-10A cells (Espinosa-Neira, Mejia-Rangel 
et al. 2011). These studies made us speculate that FFAR1 might be involved in 
mediating these effects, as all studies incorporated long chain fatty acids, which 
are potential activators of FFAR1. Thereby we intended to study a few canonical 
markers that mediate these events. Out of a few EMT markers like E cadherin, 
D
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vimentin, snail, slug and twist we tested for (Data not shown), we identified that 
protein levels of vimentin and FAK to be upregulated in FFAR1 breast cancer 
cell line (Figure 45 A & B). Vimentin is one of the essential EMT markers, 
whose expression is generally upregulated in cancer (Hemalatha, Suresh et al. 
2013). FAK upregulation in tumor cells is correlated with increased invasion 
and metastasis, and FAK signaling promotes the formation of invadopodia and 
the emergence of an invasive cell phenotype (Hsia, Mitra et al. 2003). This is 
reflected by the emergence of mesenchymal morphology in the MCF-7 FFAR1 
cells, while the MCF-7 vector cells retained the typical epithelial morphology 
seen in the MCF-7 parent cells (Figure 45 C & D) 
 












                          
 
                     
Figure 45: FFAR1 is involved in EMT-like processes in breast cancer cells 
A) A western blot analysis performed in MCF-7 vector control and FFAR1 cell 
serum starved for 4 hours followed by oleate treatment for 4 hours. B actin is 
used as a loading control. B) quantification of A. C) Phalloidin staining of MCF-
7 wildtype, MCF-7 Vector control, MCF-7 FFAR1 showing the Cell 
morphology. The white arrows denoted in MCF-FFAR1 spots the filopodia 
B












projections. D) Quantitation of C, the number of cells with filopodia in atleast 
3 different fields is counted and normalised to wild type cells. The results shown 
is the representation of 3 independent experiments with error bars representing 
the mean ±SD, * p <0.05, ** p <0.01, *** p <0.001 N=3.  
 
4.4 Investigating the role of FFAR1 in autophagy 
 
Oleate and palmitate has been studied for its role in regulating autophagy. 
However, contrasting roles for these fatty acids has been observed. Thus, we 
went ahead to study the role of FFAR1 in mediating autophagy in breast cancer 
cells.  
4.4.1 Investigating the role of FFAR1 in modulating autophagy in MCF-7 
FFAR1 over-expression model 
 
Fatty acid, including palmitate and oleate, have been shown to regulate 
autophagy, but the mechanism underlying this effect is unknown (Tu, Zheng et 
al. 2014) (Niso-Santano, Malik et al. 2015) (Mei, Ni et al. 2011), but may 
involve the direct activation of FFARs. We selected two canonical markers of 
autophagic flux, LC3 and p62. Our results from Figure 46 B denote reduced p62 
levels, however it is not complimented with increased LC3II levels, however 
the levels of p62 is not included due to inconsistent and inconclusive results. 
Palmitate but not oleate may be involved in inducing autophagy in MCF-7 cells. 
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Figure 36: Palmitate induces autophagy in MCF-7, unlike oleate, however 
independent of FFAR1 
 
A) Western blot showing the LC3 protein levels in MCF-7 FFAR1 cells on 
200uM oleate stimulation B) LC3 and p62 level in MCF-7 FFAR1 cells on 
200uM palmitate stimulation. The cells were treated for 4 hours, during the last 
1 hour treatment, 10µM chloroquine was added. Cells were not serum starved 
for autophagy studies.The blots are representative of 3 independent 
experiments, N=3. 
4.4.2 Investigating the role of FFAR1 in modulating autophagy in MDA-
MB-231 FFAR1 over-expression model 
 
A Similar approach was followed for MDA-MB-231 over-expressing FFAR1 
cells. The cells were treated with 200uM palmitate and oleate. A significant rise 
in the accumulation of LC3II and significant reduction in p62 was observed in 
palmitate treated group (Figure 47 C), yet, FFAR1-dependent modulation was 
not noted.  












                        
 
            
Figure 37: Oleate and Palmitate induces autophagy in MDA-MB-231 cells 
independent of FFAR1 
A) Western blot showing the LC3 protein levels in MDA-MB-231 FFAR1 cells 
on 200uM oleate stimulation (B) p62 protein levels upon activation of FFAR1 
using oleate (C) Demonstrates LC3B and p62 protein levels upon palmitate 
stimulation in MDA-MB-231 FFAR1 cells. The treatment period is 4 hours, 
during the last hour of treatment period, 10uM chloroquine was added to the 
cells. Cell were not subjected to serum starvation. The blots are representative 














Discussion (Part II) 
The body of knowledge on FFAR1 in breast cancer is scant and most of the 
earlier studies have used cells with endogenous FFAR1 expression to study the 
role of FFAR1. However, MDA-MB-231 cells are an inadequate model for the 
characterization of FFAR1, because in addition to expressing FFAR1, it also 
expresses GPR120, which shares many ligands with FFAR1(Navarro-Tito, 
Robledo et al. 2008) (Figure 35). This project performed database analysis and 
made use of Curtis breast datasets and analysed the tissues for the expression of 
FFAR1 in breast carcinoma tissues, it was identified that FFAR1 is over-
expressed in ductal breast carcinoma and invasive and ductal breast carcinoma 
tissues (Figure 35). Based on the qPCR analysis, MDA-MB-231 was identified 
to have high endogenous expression of FFAR1, hence, preliminary studies were 
conducted in MDA-MB-231, to affirm the findings, and then moved on to 
engineer MCF-7, as this cell line has the little endogenous expression of FFAR1 
(Figure 36). FFAR1 was over-expressed in MCF-7 cells to ensure the study is 
focused towards obtaining the receptor-specific effects. The over-expression 
MCF-7 cells were validated for the receptor functionality using Anti-V5 
labelling and mRNA expression and receptor internalization assay (Figure 37 
A, B & C). As mentioned earlier in section1.2.1, various studies have identified 
that FFAR1 is the receptor for natural LCFAs (Le Poul, Loison et al. 2003) 
(Nilsson, Kotarsky et al. 2003) (Briscoe, Tadayyon et al. 2003) (Brown, 
Goldsworthy et al. 2003). The most predominantly present long chain fatty acids 
in plasma was shown to activate FFAR1 at the relevant physiological 
concentration range (Briscoe, Tadayyon et al. 2003). Oleate and palmitate were 
selected for our study attributing to FFAR1 activation (Hardy, St-Onge et al. 
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2005). Moving ahead, TGF-a shedding assay was utilized to validate the 
receptor activation by the natural ligands, which demonstrates that oleate and 
palmitate activates the FFAR1 in dose dependent manner with greater potency 
(Figure 38 A & B).  
The Raf-MEK-ERK signaling pathway is aberrantly activated with 
overwhelming frequency in cancer, and has profound and widespread 
downstream effects. Activated ERK can translocate to the nucleus and regulate 
various transcription factors, such as Elk1, ultimately promoting cell 
proliferation, cell survival and metastasis (Roberts and Der 2007). In a study, 
oleate was shown to induce proliferation, especially in human breast cancer cell 
line MDA-MB-231 cells (Hardy, El-Assaad et al. 2003). Various lines of 
evidence demonstrate that FFAR1 is implicated in oleate- mediated 
proliferation, firstly, oleate mediated Ca2+ was increased in MDA-MB-231 
(endogenously expresses FFAR1), secondly, oleate amplified the proliferative 
effects in FFAR1 over-expressed three different breast cancer cell lines. 
Moreover, over-expressing FFAR1 in T47D signals through PLC, MEK1/2- 
PI3K implicating its role in proliferation (Hardy, St-Onge et al. 2005). In this 
way, I decided to look into the ERK activation in MDA-MB-231 cells, and 
identified that FFAR1 could be engaged in regulating the ERK protein levels. 
Our data suggest that oleate enhances ERK activation in a time- (Figure 39 A 
& B) and dose- dependent manner (Figure 39 C & D) in MDA-MB-231. The 
rapid activation of ERK upon FFAR1 stimulation implied that ERK is probably 
direct downstream of FFAR1 signaling. Upon activation, most GPCRs exhibit 
receptor phosphorylation and β-arrestin binding, leading to receptor 
desensitization and internalization (van Koppen and Jakobs 2004)(Koppen & 
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Jakobs, 2004). This may underlie the reduction in ERK activation after 60 
minutes in our data. The dose dependency graph showed an increase in oleate-
induced ERK activation up till 200 μM, before falling at 400 μM. Consistent 
with literature findings (Hardy, Langelier et al. 2000) (Soto-Guzman, Robledo 
et al. 2008), these results demonstrated that FFAR1 activation is time and dose 
dependent.  
Phosphorylated ERK translocates to the nucleus inducing cellular proliferation 
(Roberts and Der 2007). In order to correlate with the increased activation of 
ERK, proliferation rate of MDA-MB-231 cells upon oleate application was 
studied using BrdU assay. BrdU-positive cells were increased in oleate treated 
group when compared to vector control (Figure 40 A & B) signifying the role 
of oleate in increasing proliferation in MDA-MB-231 cells. Studies have 
identified the role of oleate in promoting invasion and migration in breast cancer 
cells (Navarro-Tito, Robledo et al. 2008). Hence, we performed the wound- 
healing assay in MDA-MB-231 cells upon treatment with oleate. The rate of 
wound-healing was measured by calculating the area of scratch that is left 
uncovered after 48 hours of creating the wounds. I identified that oleate treated 
group migrated faster than the other groups however slower than the positive 
control group treated with 10% FBS (Figure 41).   
In addition, to using MDA-MB-231 cells that express high levels of FFAR1, we 
started utilizing genetically engineered MCF-7 FFAR1 over-expressing cells. 
cAMP assay conducted in these engineered cells demonstrates no change in 
cAMP concentration suggesting that FFAR1 is more likely to couple to Gaq/11, 
rather than Gai/o (Figure 42). FFAR deorphanisation study has demonstrated that 
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ligand mediated action of FFAR1 is not inhibited by PTX treatment, implying 
the absence of Gai/o coupling, which is in line with our observation (Briscoe, 
Tadayyon et al. 2003) (Nilsson, Kotarsky et al. 2003) (Schroder, Janssen et al. 
2010), However there are studies that support  strong (Itoh, Kawamata et al. 
2003)  to weak coupling  (Yonezawa, Katoh et al. 2004) of FFAR1 to Gai/o.  
The receptor specific activation of ERK activation was further demonstrated by 
utilizing the most potent and specific receptor antagonist, GW1100 and 
GW9508 receptor agonist. GW9508 and GW1100 are most commonly used 
FFAR1 modulators. Various studies have shown the function of GW9508 in 
enhancing the receptor mediated intracellular Ca2+ release and potentiation of 
GSIS and FFAR1 antagonist, GW1100- mediated inhibition of these effects 
(Briscoe, Peat et al. 2006).  Thus, I planned to use the two synthetic ligands for 
observing the ERK activation upon their application to cells. Initially, GW1100 
was validated for its functioning using TGF-a shedding assay (Figure 43), 
However the validation of GW9508 compound was performed and was 
identified that the compound is unresponsive to the TGF- a shedding assay. In 
Figure 43, MCF-7 FFAR1 cells when subjected to natural ligand, oleate and 
GW9508, FFAR1 synthetic agonist, ERK activation was significantly further 
improved in GW9508 synthetic agonist group compared to the oleate group. 
Same figure C & D demonstrate, MCF-7 FFAR1 cells treated with oleate having 
an increased ERK activation, which was blocked to the level of vehicle treated 
group by the GW1100 synthetic compound. (Figure 44 A, B, C & D).  
Epithelial mesenchymal transition (EMT) mechanisms is an integral component 
in the progression of many epithelial tumours. Furthermore, the defining 
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characteristic of cells that have undergone EMT is their ability to separate from 
neighboring cells and penetrate into and through surrounding tissues (Radisky 
2005), which is a key process in the metastasis of cancer cells. FFAR1 
overexpression in the MCF-7 FFAR1 cells caused the upregulation of 
mensenchymal markers Vimentin and FAK (Figure 45 A & B). To note, 
vimentin activation is generally too weak to be clearly detected in MCF-7 cells, 
as the cell line is of epihelial nature, whereas vimentin is a specific marker 
ascribed to mesenchymal cells, this attributes to the blots failing to show clear 
protein bands. FAK upregulation in tumour cells is correlated with increased 
invasion and metastasis, and FAK signaling promotes the formation of 
invadopodia and the emergence of an invasive cell phenotype (Hsia, Mitra et al. 
2003). This is reflected by the emergence of mesenchymal morphology in the 
MCF-7 FFAR1 cells (Figure 45 C & D). We made use of oncomine database to 
study the expression level of FFAR1 in different breast carcinomas. Curtis 
breast datasets, exhibits high expression levels of FFAR1 in invasive ductal and 
lobular carcinoma. This significant increase in FFAR1 expression, signifies that 
FFAR1 is over-expressed in breast cancer, specifically in invasive types of 
breast cancer tissues thus enabling the progression of tumor through EMT and 
cell proliferation pathways (Figure 46).  
In conclusion, FFAR1 is shown facilitate tumor- promoting processes in breast 
cancer cells (Figure 48). We show that, FFAR1 is involved in ERK upregulation 
and mediated proliferation, applying the pharmacological approach, FFAR1 
synthetic ligands shows the receptor specific modulation of ERK. In addition, 
the role of FFAR1 in EMT-related processes like migration, upregulated 
mesenchymal markers and related emergence of filopodia was identified.  
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I went on to study the role of FFAR1 in fatty acid mediated autophagy. Fatty 
acids, particularly oleate and palmitate have been shown to regulate autophagy, 
although contradictory roles in regulating autophagy have been reported. 
Palmitate and oleate in general, is shown to induce autophagy in most of the 
studies (Tu, Zheng et al. 2014) (Niso-Santano, Malik et al. 2015) (Mei, Ni et al. 
2011) (Niso-Santano, Malik et al. 2015). On the contrary, there is evidence 
showing oleate is not involved in mediating autophagy (Tu, Zheng et al. 2014). 
A study has identified that palmitate stimulates autophagy in pancreatic ß cells 
playing a protective role towards pancreatic cells (Choi, Lee et al. 2009). This 
study made us speculate the possible involvement of FFAR1 in mediating the 
effects, as the study was conducted in pancreatic ß cells, where the predominant 
distribution of FFAR1 is established. We begun our study in two cell lines 
MCF-7 and MDA-MB-231 cells over-expressing FFAR1. To note, in our 
previous figure 36 we show an increased endogenous expression of FFAR1 in 
MDA-MB-231, however, we identified a sub-line of MDA-MB-231 cells that 
demonstrate low endogenous expression of FFAR1 (data not shown). Hence we 
over-expressed the receptor in this cell line. Also, it is known that MCF-7 is a 
BECN1 mutated cell line (Maycotte and Thorburn 2014), an essential 
machinery in regulating autophagy, therefore basing the autophagy study 
exclusively on MCF-7 might not be advisable, hence we decided to use the new 
MDA-MB-231-FFAR1 low cells to over-express FFAR1. The over-expression 
sysmtem validation is shown in figure 37 B & C. The conversion of LC3I to 
LC3II is a conventional marker studied in autophagy process (Huang, Scott et 
al. 2000). In addition to LC3, p62 has recently started gaining importance for 
its indispenseable role in directly interacting with LC3 protein (Bjorkoy, 
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Lamark et al. 2005) the detailed role of LC3 and p62 is dealt with in section 
1.5.3. According to our data, in figure 46 A, MCF-7 FFAR1 treated with oleate 
shows no change in LC3II accumulation compared to vector control group, 
while the same cells treated with palmitate showed a slight but insignificant 
increase in LC3II levels along with palmitate-mediated significant reduction in 
p62 was observed (Figure 46 B). Taken together, FFAR1 mediated LC3II 
accumulation and p62 reduction is not observed in MCF-7 FFAR1 cells. Figure 
47 shows the data from MDA-MB-231 FFAR1 cells subjected to oleate and 
palmitate treatment. Oleate mediated LC3 levels remains unchanged in 
comparison to vector control cells (Figure 47 A), nevertheless, oleate- 
stimulated reduction in p62 denotes the autophagy induction by oleate in MDA-
MB-231 cells, however FFAR1 involvement was not noted (Figure 47 B). 
Palmitate applied to MDA-MB-231 FFAR1 cells induces a significant LC3II 
accumulation correlating with significant reduction in p62 protein levels, 
however, the involvement of FFAR1 is not represented (Figure 47 C). In 
summary, we show that oleate and palmitate triggers autophagy processes in 
breast cancer cells, however this appears not to be regulated by FFAR1. The 
rationale for FFAR1- independent, fatty acid mediated autophagy effects may 
be mediated through the steroid nuclear receptors known as peroxisome 
proliferator-activated receptors (PPARs) which includes three members: 
PPARα, PPARβ and PPARγ. The endogenous ligands for these receptors are 
free fatty acids and eicosanoids (Sampath and Ntambi 2004, O'Flaherty, Rogers 
et al. 2005). PPARγ mediated Dietary fatty acid dependent gene transcription 
was identified for the first time in 1992 (Gottlicher, Widmark et al. 1992). In 
the same study, it was identified that linoleate and arachidonic acid activated 
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this receptor by using a chimeric receptor approach. This led to the conclusion 
that various saturated and unsaturated fatty acids (particularly palmitate), 
linoleate, arachidonic acid and oleate are the potent endogenous ligands for 
PPARγ (Gottlicher, Widmark et al. 1992). Such nutrient sensing nuclear 
receptors like PPARγ are chief integrators of metabolic events. Multiple studies 
have shown the role PPARα in regulating autophagy (Lee, Wagner et al. 2014) 
(Settembre and Ballabio 2014). More specifically, the role of these receptors in 
cancer autophagy has been reported, it is shown that troglitazone, a synthetic 
ligand of PPAR-γ increases AMPKα, reduces p70S6 kinase phosphorylation, 
thereby stimulating autophagy. In addition, the report shows that PPARs makes 
use of EGFR, which serves as a transducer of intracellular signaling of PPAR 
ligands leading to induction of autophagy (Kletzien, Clarke et al. 1992). Taken 
together, the fatty acid mediated augmentation of autophagy markers (LC3 and 
p62) we observed may be attributed to an alternative fatty signaling mechanism 
that includes PPARs or PPAR- mediated trans activated EGFR signaling or even 
the other receptor for LCFAs i.e., GPR120, rather than FFAR1.  
 
	 145	
               
Figure 38: FFAR1-mediated regulation of critical effectors of tumorigenic 
pathways   
Significance and Limitations of the study 
The study demonstrates the role of FFARs in breast cancer. For the first time, 
we show the role of FFAR1, FFAR2 and FFAR3 in regulating the essential 
effectors EMT-Metastasis pathways, also FFARs mediated ERK/p38MAPK 
was studied. This study identifies that FFAR2 and FFAR3 expression in breast 
cancer cells reverses EMT and inhibits proliferation, whereas FFAR1 
stimulation is determined to enhance the activation of the ERK levels, the effect 
was further validated by utilizing FFAR1 synthetic agonist and antagonist. In 
addition, MET markers- vimentin and FAK is also observed to be altered 












The study was based on cancer cell models. The cell lines used in the study were 
limited to MCF-7 and MDA-MB-231, however the cells were selected based on 
the FFAR expression pattern and cellular phenotype, in order to maintain an 
unbiased approach. To note, in this demonstration, FFAR2 and FFAR3 
mediated EMT - and proliferation- related effects studied was specific to the 
triple negative status cell line MDA-MB-231, which signifies the potential 
implication to particular breast cancer subtypes, however further validation in 
various other similar cell types and In vivo model is required before making a 
conclusive statement. This study has identified a number of potential markers 
to be modified upon receptor stimulation, which opens window for more 
definitive investigation in future. However, extensive studies involving pathway 
inhibitors for the MAPK and YAP will demonstrate the role of FFARs in 
mediating phenotypic effects such as, proliferation, invasion and migration.  
In addition to genetic modification of over-expressing FFAR1, pharmacological 
approach was adopted. Whereas the similar approach was not followed for 
FFAR2 and FFAR3, due to the unavailability of well-defined and validated 
synthetic ligands for receptor 2 and 3. Genetic knock down of the receptors is 
an additional method to support the findings. It requires identification of cell 
that endogenously expresses an ample level of the receptors to be able to 
knockdown the expression or knocking down the receptor expression in an over-
expression engineered cell line. Our objective towards autophagy study is to 
identify the participation of FFAR1 in mediating the fatty acid- stimulated 
autophagic effects. Our demonstration shows that palmitate and oleate are 
capable of inducing autophagy in breast cancer however independent of FFAR1. 
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Since the overall aim of the project is to characterize functions of FFARs, 
FFAR1 independent autophagy was not pursued further.  
Concluding remarks  
Cumulatively, we demonstrate complex and contrasting roles of the individual 
FFAR subtypes in breast cancer cells: while LCFA receptor FFAR1 promotes 
proliferation and migration, the SCFA receptors FFAR2 and FFAR3 limit the 
progression of EMT. FFAR2 is shown to enhance the activation of epithelial 
markers in triple negative, mesenchymal- like breast cancer cell line, suggesting 
its role in reversing EMT process in breast cancer. Similarly, FFAR2 also 
influences the proliferation inhibition through inactivating YAP pathway. On 
the other hand, FFAR3 was identified to inhibit proliferative marker 
ERK/P38MAPK. Both FFAR2 and FFAR3 expression reduced the visible 
cytoskeletal fibre alteration denoting less morphological changes. In addition, 
the invasiveness of the cells reduced upon FFAR2 and FFAR3 expression. The 
cells were sensitized to chemotherapeutic drugs upon the receptor expression. 
From our findings, we suggest that FFAR2 and FFAR3 regulates anti-cancerous 
signaling pathway by inhibiting metastasis- and proliferation- related effectors.  
On the contrary, FFAR1 is represented to play a progressive tumorigenic role. 
FFAR1 is shown to be involved in regulating ERK and enhance the 
mesenchymal markers along with phenotypic morphological alterations. Based 
on which, it is inferred that FFAR1 signals towards tumor-progressive 
pathways, thus exacerbating breast cancer condition.  
This study has essentially characterized the free fatty acid receptors for their 
participation in modulating breast cancer. The members of the same family of 
receptors are shown to regulate breast cancer in opposing manner. For the first 
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time, we show the involvement of these receptors in regulating the important 
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